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Abstract 
B ackground and Purpose: Omega-3 fatty acids are essential for brain development 
but their dietary intake is low. Controlled trials of omega-3 fatty acids in Attention 
deficit/hyperactivity disorder (ADHD) suggest benefit but have limitations. The pur-
pose was to conduct a small clinical trial to serve as a pilot study. 
Met hods: This was a randomized, double blind, placebo controlled trial, sup-
plementing youth (6-17 years old) with ADHD, with an omega-3 fatty acid. supplement 
or identical placebo for 6 months. The primary outcome measure was the Conners' 
ADHD scale. 
Results: There were recruitment problems requiring inclusion/exclusion crite-
ria revision. Seven (of 10) patients per group were recruited. Withdrawal was a problem; 
57% of participants did not return following treatment assignment. One participant 
per group completed the study. Treatment assignment did not affect study withdrawal. 
Tolerability was a major reason for withdrawal in both groups. No differences in st udy 
outcomes were detected. 
Conclusions: Several limitations and potential protocol enhancements were 
identified, including a change of supplement. No conclusions could be made regarding 
the efficacy of this supplement in the treatment of ADHD. 
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Chapter 1 
Introduction 
1.1 Attention D eficit /Hyperactivity Disorder 
1.1.1 Description of the Condition 
Attention deficit/hyperactivity disorder (ADHD) is the most common de\·elopmental 
disorder of childhood, with prevalence estimates ranging from 4% to 15% for school 
age children [1, 2, 3, 4, 5] . ADHD is characterized by sustained problems with age-
inappropriate levels of inattention, hyperactivity and/ or impulsivity in a variety of 
settings [5]. There are three subtypes of ADHD: a predominantly inattentive sub-
type, a predominantly hyperactive-impulsive subtype, and a combined inattentive and 
hyperactive-impulsive subtype [5]. There i little information available regarding the 
proportions of ADHD subtypes within non-clinical and clinical populations [1, 2, 4]. 
Anecdotally, the majority of cases are the combined subtype, with a roughly equal 
number of inattentive and hyperactive/impulsive subtypes. ADHD is more prevalent 
in boys. The gender ratios range from 2:1 (Males:Females) to 9:1 [5]. 
1 
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Challenges associated with ADHD can include academic struggles, social dys-
function and poor self esteem [1, 2] . Youth with ADHD often have comorbid diagnoses, 
including learning disabilities, disruptive behaviour disorders, tic disorders, anxiety 
disorders and major depression [1, 2]. The diagnosis is associated with a higher risk 
of negative outcomes, such as substance abuse, delinquency, school withdrawal and 
motor vehicle accidents [1, 2]. Between 50% and 75% of youth with ADHD will have 
sufficient symptoms to warrant continued diagnosis with ADHD as adults [1, 2]. 
1.1.2 A etiology 
Evidence suggests that several factors contribute to the development of the diagno-
sis of ADHD , including genetic factors , neuroanatomical abnormalities, psychosocial 
factors, pregnancy and delivery complications, and environmental factors , such as pre-
natal exposure to cigarettes or alcohol [2, 1 J. Heritability is believed to account for 
approximately 75% of the aetiology of ADHD [2, 1]. 
The dopamine neurotransmitter system is likely involved in the pathoetiology 
of ADHD [2 1]. Medications prescribed in the management of ADHD increase th 
availability of dopamine in the brain [2, 1]. Several genes related to the dopamine 
pathway have been linked to ADHD , including the dopamine D4 and D5 receptors , 
dopamine-,8-hydroxylase and dopamine transporter genes [2, 1]. Neuroimaging studies, 
including functional assessments, have identified differences in dopamine pathways in 
children and adults with ADHD [2, 1] . 
1.1.3 Diagnosis of Attention D eficit / Hyperactiv ity Disorder 
The diagnosis of ADHD is based on diagnostic interviews. These interviews are sup-
ported by collateral history, psychometric assessment, behaviour rating scales and 
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direct observation. Diagnosticians apply validated criteria for ADHD from t he Di-
agnostic and Statistical Manual of Mental Disorders: Fourth Edition, Text Revision 
(DSM-IV TR) [5, 2, 1, 3]. 
1.1.4 Treatment for Attention Deficit/Hyperactivity 
Disorder 
The recommended treatment for ADHD consists of a combination of pharmacological 
and non-pharmacological interventions [1, 2, 3, 4]. First-line pharmacological options 
include stimulant medications, such as methylphenidate and dextroamphetamine, and 
non-stimulant medications, such as atomoxetine [1, 2, 3, 4]. 1 on-pharmacological 
intervention include parent effectiveness training, behaviour management plans and 
psychological interventions [1, 2, 3, 4] . However, behavioural therapies do not appear 
to be effective without co-administration of medication [6] . 
Evidence suggests that stimulant medications are effective in improving ina t-
tention and behavioural symptoms [1, 2, 3, 4]. However, this evidence suggests that 
these medication are less effective in improving achievement and cognition [1, 2, 3, 4]. 
Benefits associated with medical treatment for ADHD do not persist once they are 
discontinued [1, 2, 3, 4] . All subtypes of ADHD respond similarly to pharmacological 
interventions [1, 2, 3, 4]. 
fany patients receiving maximal stimulant therapy still have considerable 
disability and dysfunction associated with their illness [1, 2, 3, 4]. As well, up to 30% 
of children with ADHD do not respond to conventional pharmacotherapies [1, 2, 3, 4]. 
Numerous side-effects are associated with the medications u ed in the t reatment 
of ADHD, including weight loss, growth restriction, tics, and insomnia [1, 2]. Many of 
these stimulant medications have considerable abuse potential [1, 2] . These medications 
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can worsen comorbid conditions, such as tics [1, 2]. Given the limitations in present 
treatments for ADHD , some families explore alternate treatments [3, 2] . 
There is a wide variety of alternate treatments available in the treatment of 
ADHD [3, 2] . In general, rigorous and objective analysis of these therapies has not been 
conducted, leading to a lack of empirical support in scientific literature. Parents and 
guardians nonetheless explore these treatment options, sometimes with but at other 
times without the knowledge, support or guidance of their health care professionals. 
There is consequently a need for competent and objective analysis of these alternate 
treatments. 
Of the available alternate treatment for ADHD, omega- 3 fatty acid supplemen-
tation is widely available, in the forms of dietary supplements and food additives [3]. 
Omega-3 fatty acid supplementation appear to be the most studied and most promi -
ing of the alternative treatments of ADHD [7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 
20, 21 , 22, 23, 24]. Several essential variables are presently unknown [7]. These include 
clear evidence of therapeutic effect, optimal dosing strategies, the length of time to 
the onset of any therapeutic action, and the duration of any therapeutic action. 
1.2 Omega- 3 Fatty Acid Supplementation 
Omega- 3 fatty acids are essential for huma11 brain development and health [25] . The 
longer-chain, highly unsaturated fats fatty acids , particularly eico apentaenoic acid 
(EPA) (Figure 1.1) docosahexaenoic acid (DHA) (Figure 1.2) are most important for 
brain development and function. DHA is the major polyunsaturated fatty acid in the 
adult brain [26] . EPA and DHA can be synthesized within the body from the essential 
fatty acid precursor alpha-linolenic acid, although this conversion process is not very 
efficient in human , particularly males [27, 28]. By historical standards, dietary intake 
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of omega- 3 fatty acids is very low in many modern developed countries. The key 
omega- 3 fatty acids (EPA and DHA) are found in high quantities only in fish and 
other seafood [25]. 
Figure 1.1: Eicosapentaenoic Acid (EPA) Structure. From "Eicosapentaenoic acid 
structure," by K. Harrison, 2007, http:/ / www.3dchem.com/ molecules.asp?ID= 380. 
Copyright 2007 by Karl Harrison. 
Several converging lines of evidence suggest a connection between omega- 3 fatty 
acid insufficiency and ADHD, as well as a role for omega- 3 fat ty acid supplementation 
in the treatment of ADHD. Several studies have identified clinical and hematologic signs 
and symptoms of essent ial fatty acid insufficiency among a high proportion of children 
and adolescents with ADHD and other disruptive behaviour disorders when compared 
with controls [29, 30, 22, 31 , 32]. Both ADHD and omega- 3 fatty acid insufficiency are 
more prevalent in males [29, 30, 22, 31, 32]. Comparable abnormalit ies in dopamine 
metabolism are evident in both ADHD and omega- 3 fatty acid insufficiency [33, 34]. 
This apparent connection between ADHD and omega- 3 fatty acid insufficiency suggests 
that correction of this insufficiency via supplementation might lead to an improvement 
in ADHD symptomatology. 
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Figure 1.2: Docosahexaenoic Acid (DHA) Structure. From "Docosahexaenoic acid 
structure," by K . Harrison, 2006, http:/ /www.3dchem.com/molecules.asp?ID=238. 
Copyright 2006 by Karl Harrison. 
It is possible to reliably and non-invasively identify omega 3 fatty acid insuffi-
ciency using a symptom questionnaire, as described in subsection 3.10.5 and illustrated 
in Appendix C [29, 30, 22, 31 , 32]. Presently, there is speculation as to the relevance 
of these signs and symptoms in patients with ADHD in predicting treatment outcome. 
1.3 Literature review 
There was a recent Cochrane review, conducting a meta-analysis of clinical trials 
involving the treatment of youth with ADHD with supplements containing polyun-
saturated fatty acids, including omega 3 and omega- 6 fatty acids, separately or 
together [7]. Eighteen publications describing 13 clinical trial met inclusion crite-
ria [8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 1 , 19, 20, 21, 22, 23, 24] . 
The apparent efficacy of polyunsaturated fatty acid supplementation in youth 
with ADHD varied among the studies in thi meta-analysis [7] . Two trials of parallel 
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design, involving omega-3/6 polyunsaturated fatty acids compared to placebo sug-
gested improvement (97 participants; risk ratio 2.19, 95% confidence interval ( CI) 1.04 
to 4.62) [17, 22]. Five trials found no statistically significant differences in parent-rated 
total ADHD symptoms (413 participants; standardized mean difference (SMD) -0.17, 
95% CI -0.3 to 0.03) [14, 18, 21, 20, 35, 22, 23]. Six trials found no statistically 
significant diff rences in parent-rated inattention ( 469 participants; SMD -0.04, 95% 
CI - 0.29 to 0.21) [14, 18, 19, 20, 35, 22, 24]. Five trials found no stati tically significant 
differences in parent-rated hyperactivity / impulsivity ( 416 participants; SMD - 0.04, 
95% CI -0.25 to 0.16) [14, 18, 19, 21, 20, 35, 22]. Four trial found no statistically 
significant differences in teacher-rated total ADHD symptom (324 participants; SMD 
0.05, 95% CI - 0.1 to 0.27) [14, 1 , 19, 35]. Three trials found no statistically sig-
nificant differeuces in teacher-rated iuatteution (260 participams; SMD 0.26, 95% CI 
- 0.22 to 0.74) [14, 18, 22]. Three trials found no statistically significant differences in 
teacher-rated hyperactivity/impulsivity (259 participants; SMD 0.10, 95% CI - 0.16 
to 0.35) [14 1 , 22]. These negative study outcomes do not support omega- 3 fatty 
acid supplementation in the treatment of ADHD. 
The meta-analysis identified several key limitations among the included stud-
ied [7]. These weaknesses included small sample sizes, variability of selection criteria, 
variability of the type and dosage of supplementation, and short follow-up times ( 4 to 
16 week ). It is difficult to conclude whether these negative re ult are indicative of a 
lack of efficacy (i.e. a true negative) or a failure of t hese studies to recognize efficacy 
as a result of their limitations (i.e. a fal e negative) . 
Due to the limitations of previou studies and the early stage of this research, 
no standard has yet been defined regarding a source for omega- 3 fatty acid supple-
mentation dosage or relat ive proportions of omega-3 fatty acids of iuterest , including 
EPA and DHA. Fi h oils have been the most common and the most readily available 
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source [36, 22 16, 37]. These supplements come in a variety of doses , capsule sizes 
and alternate preparations, such as soft-chews and syrups. This is an important and 
practical consid ration in clinical practic with children, who may find swallowing 
large capsules difficult. 
Dosages of EPA studied ranged from 0 mg per day [22] to 558 mg per day [37]. 
Dosages of DHA studied ranged from 17 4 mg per day [37] to approximately 510 mg per 
day [15] . The ratios of DHA to EPA studied have ranged from approximately 6:1 [22] 
to 1:3 [37]. These relative proportions of EPA and DHA seem to be largely determined 
by the unique characteristics of each supplement used in the studies. Commercially 
available omega- 3 fatty acid fish oil upplements generally have a ratio of EPA:DHA 
between 2:1 and 1:2. 
Omega-3 fatty acids are essential nutrients and are regarded as safe in doses 
much higher than those used in this and similar studies [38]. o ignificant difference 
in rates of adverse effects between polyun aturated fatty acids and placebo vvas found 
in any of the trials included in the previously noted meta-analysis [7]. Side effects of 
high doses of fish oils can include digestive ymptoms such as nausea. belching or loose 
stools [3 ]. 
1.3.1 ADHD Subtypes 
The Cochrane Review [7] did not compar the efficacy of omega-3 fatty acid supple-
mentation among ADHD subtype . There is no evidence to suggest that omega- 3 
fatty acid supplements are more or les efficacious depending on ADHD subtype [8, 9, 
10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24] . 
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1.3.2 Concurrent Treatment 
As described in subsection 5.3.1 and Table 5.1 , some of the studies included in the 
Cochrane Review [7] permitted ongoing use of conventional treatments for ADHD, 
usually stimulants [16, 22, 24]. Participants in these trials continued to receive their ex-
isting therapies throughout the trials, both pharmacological and non-pharmacological 
interventions. Other included studies did not permit concurrent use of such t reat-
ments [18, 39, 23, 17]. 
As outlined in section 3.3, this study permits ongoing prescription of existing 
pharmacotherapies for ADHD and comorbid illnesses, as well as continued part icipation 
in non-pharmacological intervent ions, such as those described in subsection 1.1.4. This 
design is compatible with some studies [16, 22, 24] and not others [18, 39, 23, 17]. The 
primary reason for permit t ing concurrent t herapies is clinical relevance. As explained 
in subsection 1.1.4, the recommended treatment for ADHD is multimodal [1, 2, 3, 4] . 
At present, omega- 3 fatty acid supplements are of interest as possible complementary 
therapies to established interventions. This study therefore seeks to assess the efficacy 
of these supplements in this clinical context. 
This choice to permit concurrent therapies does present several potential chal-
lenges. A greater treatment effect will likely be required to differentiate a t reatment 
effect of t he study supplement from the effect of some other variable, such as concurrent 
therapies. This challenge will undoubtedly affect t his pilot study, with a small sample 
size. A follow-up study based on this protocol would need to take this challenge into 
account when calculating sample size. 
The heterogeneity of these existing therapies presents a related challenge. Dif-
ferences in the efficacies of t hese concurrent therapies could introduce another variable 
that could mask a treatment effect from this omega- 3 fatty acid supplement. vVhile 
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individual patients may preferentially respond to one intervention over another , on a 
clinical populat ion level, there are no clinically significant differences in the efficacy of 
the first-line therapies for ADHD [1, 2, 3, 4] . A follow-up study based on this protocol 
would need to ensure proper randomization of the study population and adequate 
sample size to address this challenge. 
1.3.3 Outcome Measures 
As discussed in section 1.1, ADHD is a complex, multifaceted condit ion [1, 2, 3, 4, 5]. 
As a result, researchers and clinicians employ a variety of subjective and objective as-
sessment tools to assess the severity of ADHD symptomatology, the cumulative burden 
of illness, and response to treatment. The high rates of comorbidity further complicates 
this challenge, demanding outcome measures that provide a holistic assessment. 
The st udies included in the recent Cochrane Review [7] employ a combination 
of subjective and objective measures to quantify baseline ADHD severity and response 
to treatment [8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24]. They 
assess both specific ADHD symptomatology, as well as broad measures of patient 
function. As the primary outcome measure, the meta-analysis assessed the change 
in ADHD symptoms as measured by validated scales, such as the Conners Rating 
Scales [40] or Child Behaviour Checklist [41 J. The Conners Rating Scales are described 
in subsection 3.10.2. The Child Behaviour Checklist is a comparable rat ing scale. These 
studies include objective measures of ADHD symptomatology among their secondary 
outcome measures, such as the Conners' Continuous Performance Test II [42], which 
is described in subsection 3.10.3. 
To address the inherent complexit ies of assessing ADHD , and permit compari-
son with related research, t his st udy employs these accepted and validated outcome 
measures. These measures are discussed in section 3.10. 
Chapter 2 
Purpose 
2.1 Rationale 
Existing trials of omega- 3 fatty acid supplementation in youth with ADHD have been 
hampered by numerous limitations and have yielded largely negative outcomes [7]. The 
goal of this trial was to conduct a small clinical trial employing a protocol designed 
to address many of the limitations identified in other studies. The study population, 
clinical setting, and length of study were all chosen to reflect clinical practice. Supple-
mentation rather than replacement of existing treatments was chosen to reflect current 
best practices. In addit ion to assessing the primary and secondary outcomes, this t rial 
was also intended to serve as a pilot study, to establish feasibility of a fu ture larger 
potential trial and to optimize the study protocol. 
11 
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2.2 Scientific Question 
In children and adolescents meeting the study's inclusion and exclusion criteria, is 
the supplementation of existing and stable treatment for ADHD with a fish oil sup-
plement containing omega-3 fatty acids superior to supplementation with a placebo 
in improving symptoms of ADHD, as measured by the teacher rated version of the 
Conners Third Edition (Global Index: Total Score subscale)? 
2.2.1 Null Hypothesis 
The null hypothesis of this study is: there is no change in symptoms of ADHD as 
measured by t he Conners Third Edition: Teacher Report: Global Index: Total Score 
( C3T-T) after six months of supplementation with a fish oil supplement containing 
omega-3 fatty acids versus a placebo. 
2.3 Alternate Hypothesis 
The alternate hypothesis of this study is: there is an improvement in symptoms of 
AD HD as measured by the C3T-T (a decrease in the mean T -score by at least 12) 
after six months of supplementation with a fish oil supplement containing omega-3 
fatty acids versus a placebo. 
Chapter 3 
Methods 
3.1 Type of Research Design 
This was a randomized , double-blind, placebo-controlled augmentation trial involving 
treatment in parallel groups for six months. Active t reatment was an orange flavoured 
syrup containing omega- 3 fatty acids. The placebo was a similar orange flavoured 
syrup. All primary and secondary outcome measures were obtained at pre-t reatment 
baseline and 6-month follow-up points. This frequency of follow-up was intended to 
reflect standard clinical practice. 
3.1.1 Length of Study 
As discussed in subsection 1.1.4, the length of time to the onset of any therapeut ic 
action and the duration of this action are unknown at present [7]. A study length of 
six months was chosen for several reasons: it was in keeping with the longer of the 
completed studies at the time [7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 
23, 24]; it was thought to be sufficiently long to establish whether there are at least 
13 
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short-term to mid-term therapeutic effects; and it was thought to be long enough to 
identify short-term and mid-term problems with the protocol, active treatment and 
placebo. 
3. 2 Ethics Approval 
Approval was sought and granted through the local health research ethics authority. 
Initially, this was the Human Investigation Committee, Faculty of Medicine, Memorial 
University of Newfoundland. As of July 1, 2011, The Health Research Ethics Author-
ity Act came into force. Authority thereafter passed to the Health Research Ethics 
Authority. 
3.3 Eligibility Criteria 
3.3.1 Inclusion Criteria 
Potential part icipants were eligible with the following inclusion criteria: · 
1. Age from 6- 17 years. 
2. At tending the Janeway Hospital Child and Adolescent Outpatient Psychiatry 
Clinic in St. John's , Newfoundland and Labrador, Canada. 
3. A diagnosis of ADHD , made by their treating psychiatrist, using DSM-IV TR 
criteria [5]. The severity of ADHD symptoms present at the time of enrolment 
was not used as either an inclusion or an exclusion criterion . 
4. Currently receiving medical treatment for ADHD , taking any combination of 
stimulant or non-stimulant medications at doses that had been stable for at least 
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12 weeks, other than dosage adjustments to account for growth (many of the 
treatments for ADHD are dosed according to patient weight). Stimulant medi-
cations include any preparations of methylphenidate, dextroamphetamine, and 
amphetamine salts. Non-stimulant medications included atomoxetine, clonidine, 
bupropion, venlafaxine, and tricyclic antidepressants if prescribed for the treat-
ment of ADHD. Participants could avail of non-medical treatments for ADHD , 
such as behaviour management at the time of enrolment and at any time during 
the study. 
Note: The choice to permit concurrent use of existing therapies is discussed in 
subsection 1.3.2, including potential limitations and challenges. 
3.3.2 Exclusion Criteria 
Potential participants were ineligible with the following exclusion criteria: 
1. Comorbid diagnoses of Oppositional-Defined Disorder, Conduct Disorder, Sub-
stance Abuse, Substance Dependence, Learning Disability, Mental Retardation 
(IQ :::; 70) , or Pervasive Developmental Disorder , diagnosed by their treating 
psychiatrist according to DSM-IV TR criteria [5]. 
2. Changes to medications for the treatment of ADHD within the past 12 weeks, 
other than dosage adjustments to account for growth. 
3. Significant comorbid medical illness, as judged by the pat ient 's t reating psychia-
trist. 
4. Failure to complete all baseline measures prior to the randomization/ pre-treatment 
clinic visit . 
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Potent ial part icipants were not excluded on t he basis of comorbid psychiat ric 
conditions not explicitly listed in t he above exclusion criteria , including mood and 
anxiety disorders, or on t he basis of any medications or non-medical t reatments they 
were receiving for these condit ions. No restrictions on use of such t reatments during 
the trial were made. An exclusion log was recorded . 
The diagnoses referred to in the eligibility criteria were based on clinical inter-
view by the part icipants ' treating psychiatrists. 
3 .3.3 M o dification of t he Inclusion / Exclusion Criteria 
As discussed in section 3.4, study enrolment was slow. T he referring psychiatrists 
identified the exclusion criteria as t he greatest barrier t o recruit ment. They reported 
high rates of comorbid diagnoses that precluded enrolment among their clinic popula-
t ions. In consultation with the supervisory committee, an amendment was submitted 
t o and approved by the Human Investigation Committee, changing the inclusion and 
exclusion criteria. This change permitted the enrolment of patients with Learning Dis-
abilities and comorbid disruptive behaviour disorders, including Oppositional Defiant 
Disorder and Conduct Disorder. Following this change , no addit ional patients were 
excluded based on the revised inclusion/exclusion criteria. 
3 .4 Study Enrolment 
Study enrolment was slow to begin , with 19 weeks passing from the initiation of study 
enrolment to enrolment of the first patient. Ten participants were enrolled over the next 
13 weeks, aft er which there were no further enrolments until the inclusion and exclusion 
criteria were changed (sect ion 3.3), 62 weeks after the initiation of study enrolment 
and 29 weeks following the enrolment of t he last preceding study participant. Another 
CHAPTER 3. METHODS 17 
4 participants were then enrolled over the next 10 weeks. Another approximately 7 
weeks passed without further patient enrolment, after which the study was closed to 
further enrolment. Enrolment was closed at that time (April, 2011) due the study 
design, which precluded further enrolment until September, 2011 because of the need 
for repeated assessments to be completed by teachers within the same academic year. 
As describ d in section 3.5, all the recruiting physicians were geographically 
located in the same clinic area. In addition to the planned monthly recruitment 
reminders, the physical proximity also permitted frequent informal reminders, about 
once weekly. 
Slow recruitment was an early concern. Initially, the principal investigator and 
recruiting physicians believed there were enough eligible patients in their practices and 
that recruitment would therefore improve given time. It became increasingly clear that 
time alone would not improve matters. The principal investigator consulted with the 
other recruiting physicians and the rna ters supervisory team to explore options. Many 
options were explored, most of which are di cussed in subsection 6.5.2. As noted earlier 
in this section, the recruiting physicians had cited the restrictive exclusion criteria as 
the main barrier to recruitment. The proce s of deciding on a mean of addressing 
the slow recruitment and amending th study protocol took longer than expected. 
By the time it was clear that this change would not sufficiently hast en recruitment , 
the window of opportunity to make further changes to the protocol had ended before 
closing th study to recruitment. 
Study response rate, in terms of potentially eligible pati nts declining participa-
tion, was not recorded, nor was it identified as a concern by the recruiting physicians. 
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3.5 Sampling Methods/Recruitment 
Participants were recruited from the Child and Adolescent Outpatient Psychiatry 
Clinic of the Janeway Children's Health and Rehabilitation Centre, in St. John's, New-
foundland and Labrador, Canada. This site serves as the province's tertiary centre for 
child and adolescent psychiatry, as well as providing specialist care to the surrounding 
area. This clinic is affiliated with Memorial University of Newfoundland's Faculty 
of Medicine and Discipline of Psychiatry. The clinic employs a full-time nurse who 
functions as an outpatient nurse and research nurse. Each psychiatrist is affiliated with 
the university and regularly participates in clinical research. Throughout the study, 
the clinic employed eight child and adolescent psychiatrists, each of whom maintained 
a large practice. Six of these psychiatrists operated full-time outpatient clinics, while 
the remaining two divided their time between outpatient and inpatient practice. Each 
psychiatrist was invited to participate in the study and accepted. Each psychiatrist 
was responsible for recruiting patients from his/her clinic. He/she made the initial 
determination of eligibili ty, which was later confirmed by the re earch nurse. Monthly 
reminders were circulated among the psychiatrists regarding the study and recruit-
ment . A poster was placed in the clinic's waiting room to inform patients and their 
guardians of the study and who was eligible to participate. 
This study site was chosen for several reasons. As the province's tertiary centre 
for child and adolescent psychiatric care, it seemed likely to have access to sufficient 
numbers of patients to complete the study without requiring a second study site, which 
would compound the complexity of study administration. Patients attending this clinic 
generally have high levels of ADHD symptomatology, which was expected to increase 
the likelihood of identifying a clear response to the supplements used in this study. 
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Each potential study participant and his/her parent/guardian was initially 
approached by his/her treating psychiatrist , who outlined the nature and purpose of 
the study. If the patient and their guardians expressed interest in part icipating in the 
study, they were given the opportunity to meet the research nurse during that same 
clinic visit. The nurse provided them with the informed consent document. The nurse 
read through the consent document with each patient and his/ her guardian (s) and 
allowed them to take time to consider whether to participate in the t rial. If t he patient 
and their guardians were interested in taking part, t hey were scheduled for the first 
t rial visit. At that visit, the physician investigator discussed the consent and answered 
any questions. Once the questions had been answered by the physician, t he research 
nurse obtained the signed and witnessed consent of each parent/ guardian and the 
assent of any child/adolescent who was able to understand the nature and purpose of 
the study. Assent indicates willingness to participate in research by those too young to 
give informed consent but old enough to understand the proposed research in general. 
3 .6 Randomization 
Upon enrolment and collection of baseline data, participants were randomized to 
treatment and placebo groups. Randomization of treatment was accomplished by the 
research nurse blindly choosing a slip of paper from an envelope containing a randomly 
sorted collection of slips , each of which corresponded to a lot number of supplement 
bottles containing either placebo or active ingredient. 
3.7 Blinding 
T he treatments were coded so that participants, clinicians and the research nurse were 
blinded to treatment assignment. A sealed group assignment registry was maintained 
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and kept in t he hospital's emergency department for consultation in the event that a 
participant required unblinding on an emergency basis. P articipants were given the 
telephone number to this emergency department with instructions to call if necessary. 
Key emergency room staff were oriented regarding this registry and printed instructions 
were attached to the sealed envelope. 
3.8 Sample Size Determination 
Previous studies involving omega-3 supplementation in patients with ADHD and 
closely related diagnoses using the C3T-T showed a reduction of 6 points in their 
T-scores [37, 36], which is considered clinically significant [40] (the raw scores of the 
C3T-T are converted toT-scores with a mean of 50 and a standard deviation of 10). 
Power calculations indicate that group sizes of 42 would detect a 6-point reduction 
in the T-score with > 80% power at the p < .05 level. The target sample size of 50 
subjects per group was therefore chosen as the optimal number for a follow-up study, 
once the feasibility of such a study was established, and the protocol optimized. 
As a pilot study, the target sample size of 10 subjects per group was chosen, for 
a total of 20 subjects. A study of this size is statistically powered to detect a reduction 
of the T-score by 12 (T-score ~ = 12) , that is a treatment effect of 1.2 standard 
deviations, with > 80% at a p < .05 level. 
3. 9 Intervention 
A survey of commercially available omega-3 fatty acid supplements was conducted , 
involving telephone and in-person contact with several pharmacists and alternative 
medicine retailers . Each supplement was evaluated based on omega- 3 fatty acid content, 
the ratio of EPA to DHA, preparation (e.g. capsule, soft-chew, gummy candy, syrup) , 
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palatability and cost. The majority of available candidates were rejected because they 
were large capsules and swallowing was expected to be a problem for some of the 
younger study participants. The soft-chews and gummy candies were rejected because 
the omega- 3 content was so low that the amount required per day would be impractical. 
The other yrups were rejected because of poor taste that was noted by several adults 
and children. The chosen supplement was utripur Genius Liquid: Kids and Teens 
(Appendix D) [43] . 
The supplement used in this study was chosen based on its commercial avail-
ability, which is important for replication and clinical use, liquid preparation for ease 
of swallowing, and a once daily do e of 5 mL of syrup. Th dosage of 4,000 mg fi h 
oil daily, consisting of 5 mL in the active treatment group was chosen as it provides 
450 mg of EPA, close to the highest used in other studies [37] and 730 mg of DHA, 
which was well within the range of dosages used in other studies [36, 22, 15, 37]. The 
palatability of this supplement was informally assessed, involving taste tests by several 
children, adolescents and adults. No concern were identified through this process. 
The supplement manufacturer was contacted regarding obtaining bulk quanti-
ties of their supplement and possibly a placeb . The manufacturer offered to supply 
both at no cost. A placebo was developed using the same packaging and supplement 
ingredients without the omega-3 fatty acids. Bottles were coded according to lot num-
bers, which aided in randomization and blinding. Each participant was randomized 
to one of two lot numb rs, one of which was the active supplement and the other the 
placebo. It was impos ible to tell from the numerically coded lot number which lot 
was active versus placebo. 
The active treatment was an orange flavoured syrup containing 4,000 mg of 
fish oil, including oils from anchovy, mackerel, sardine and tuna. Each 5 mL dosage 
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contained 450 mg of EPA and 730 mg of DHA. The placebo treatment was a syrup 
which matched the active treatment in appearance and flavour . 
Participants were instructed to take 5 mL of syrup once daily. Participants 
were provided with a supply of syrup at each clinic visit by the research nurse. This 
supply was sufficient for the eight weeks between clinic visits with at least an additional 
2-week supply to account for delays and cancelations. Participants were instructed 
to bring unused syrup to each clinic visit. Compliance was determined by measuring 
amounts of remaining syrup and using pill counts of other prescribed medications. 
3.10 Measurement s 
The primary outcome measure was the change observed during six months of treatment, 
in parallel groups, of the C3T-T [40]. Secondary outcome measures were the Conners 
Third Edition: Parent's Report (C3P) [40], the Conners' Continuous Performance 
Test II (CCPT-II) [42], the Clinical Global Impression (CGI) (Appendix A) [44], and 
the Thirst/Skin Questionnaire (TSQ) (Appendix C) [29, 30, 22]. The Conners Third 
Edition: Teacher Report (C3T) , the C3P and the CCPT-II are commercial products, 
protected by copyright and could not be reproduced as appendices. Descriptions of 
each of these measures are presented in the following paragraphs. 
A subjective outcome measure, the C3T, was chosen as the primary outcome 
variable rather than an objective outcome measure, the CCPT-II, to maintain con-
sistency with several of the key existing studies [36, 37]. As well, the CCPT-II is 
dependant on the stat e of the part icipant and the t ime of the test [42], whereas the 
C3T reports on a wide variety of behavioural characteristics over several months [40]. 
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3.10.1 Study Schedule 
As outlined in Table 3. 1, the C3T and C3P were completed immediately prior to 
init iating treatment (Visit 2, Week 2) and immediately prior to completing the t rial 
(Visit 5, Week 26). The CCPT-II and TSQ were completed at each clinic visit (Visits 
2- 5, Weeks 2, 10, 18 and 26). As the CGI measures the change from baseline, it was 
completed at each clinic visit except the initial visit (Visits 3 - 5, Weeks 10, 18 and 
26) . 
3.10.2 Conners' Rating Scales 
The Conners' Rating Scales (Parent and Teacher Versions) are self-report scales [40]. 
Clinically, they are widely used for screening, as diagnostic aides, and for monitoring 
treatment effectiveness. In research, they are also widely used as a surrogate for 
clinical diagnosis, to establish the severity of disease, and for monitoring treatment 
effectiveness. A large normative database supports the instruments ' reliability and 
valiclity. The scales take 15-20 minutes to complete. The C3T contains 59 items, while 
the C3P contains 80 items. Both scales include the following subscales: Oppositional, 
Cognitive Problems/ Inattention, Hyperactivity, Anxious-Shy, Perfectionism, Social 
Problems, Psychosomatic, Conners' Global Index, DSM-IV Symptom Subscales, and 
ADHD Index. The Conners' Global Index is the single best subscale to use as an overall 
indicator of severity of illness and level of impairment [40]. Higher scores reflect worse 
symptomatology. Scores less than 65 reflect non-clinical levels of symptomatology, 
between 65 and 69 reflect elevated (clinical) symptomatology, and greater than or 
equal to 70 reflect severe symptomatology. 
The Conners' assessments were given to the parents/ guardians of study partici-
pants during their first and last appointment (Weeks 0 and 26) (see Table 3.1). Parents 
-- -----------------------------------------------------------------------------------------------
Visit Week Purpose 
1 0 Recruitment 
2 2 Initiation of Treatment 
3 10 Follow-up Visit 
4 18 Follow-up Visit 
5 26 Final Study Visit 
Table 3.1: Study Schedule 
C3T C3P CGI CCPT-II TSQ AEI 
X X 
X X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Nurse 
X 
X 
X 
X 
X 
MD 
X 
X 
X 
X 
X 
Pill Count 
X 
X 
X 
Note . C3T = Conners Third Edition: Teacher's Report . C3P = Conners Third Edition: Parent 's Report. 
CGI = Clinical Global Impression. CCPT-II = Conners' Continuous Performance Test II. 
TSQ = ThirsLSkin Questionnaire. AEI = Adverse Efi'ect Inquiry. MD = Psychiatrist visit. 
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were asked to complete the C3T and ask the part icipants ' teachers to complete the 
C3P. Parents and teachers were directed to follow the standard inst ructions included 
with the C3P and C3T. 
3.10.3 Conners' Continuous P erformance Test II 
T he CCPT-II is an automated , objective, computer-based test widely used clinically 
and in research with ADHD [42] . Respondents are required to press the space bar when 
any letter except t he letter "X" appears. The results are considered a reflection of 
sustained attention, or vigilance, which is the essential deficit in ADHD. The computer-
generated report provides numerous indices, with the Confidence Index ( CCP T -CI) , 
reported as a percentage likelihood of having ADHD, being the best and most widely 
used single measure of severity of illness and level of impairment. CCPT-CI scores 
above 50% are suggestive of ADHD. 
The CCPT-II was administered by the research nurse. The C3T , the C3P and 
the CCPT-II were each scored and analyzed by a psychologist. 
3.10.4 Clinical Global Im pression 
The CGI is an investigator-rated scale consisting of 3 subscales: severity, clinical 
improvement and efficacy (Appendix A) [44] . The CGI severity subscale consists of 
a 7-item scale, with scores ranging from 0 (not evaluated) to 7 (extremely ill) . The 
CGI clinical improvement subscale is also a 7-item scale, with scores ranging from 0 
(not evaluated) to 7 (much worse). The CGI efficacy subscale combines a measure of 
adverse events with a measure of clinical improvement, with scores ranging from 1 
(no adverse effect/notable clinical improvement) to 16 (adverse effect is higher than 
beneficial efFects/no clinical improvement / clinically worse). A group training session 
was conducted with the participating psychiatrists on the use of the CGI scale. 
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3.10.5 Thirst/Skin Questionnaire 
The TSQ was developed by Stevens et al. [29, 30, 22] and was used with permission 
(Appendix C). T his scale ident ifies part icipants with signs and symptoms of omega-3 
fatty acid insufficiency. Stevens et al. [29, 30, 22] demonstrated that this questionnaire 
is an eflective, economical and rapid means of ident ifying participants with signs 
and symptoms of omega-3 fatty acid insufficiency, comparable to more elaborate 
and involved tests, including assays based on blood and breath. The scores of the 
individual questions were summed for a total score. Scores of four or greater are 
considered indicative of clinically significant omega-3 fatty acid insufficiency. This 
questionnaire was administered both at the beginning and at the end of t he study 
(Table 3.1). 
3.10.6 Adverse Effect Inquiry 
Adverse eflect inquiry forms (AEI) (Appendix B) were completed at each follow-up 
visit , recording the presence or absence of 8 commonly cited sicle-P-ffec.ts of omega-3 
fatty acid supplementation. 
3.10. 7 Baseline Characteristics 
T he following baseline characteristics were collected prior to randomization: age (years), 
gender, height (em) , weight (kg), blood pressure and pulse, ADHD subtype (inattentive, 
hyperactive/impulsive, or combined), medications and dosages, TSQ score, C3T (t-
scores), C3P ( t-scores) , CCPT-CI (percentage), comorbid psychiatric diagnoses (DSM-
IV TR Code). Medications were recorded at baseline and throughout the study using 
medication tracking sheets. 
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3.11 Study Schedule 
Once patients and their parent(s) or guardian (s) agreed to participate in the study 
and informed consent was obtained, they met with the research nurse (Table 3.1). 
The research nur e then oriented the parent(s) or guardian(s) to the C3P and the 
C3T, instructing them to complete the C3P themselves and have the participants' 
primary teacher complete the C3T and return both the C3P and the C3T to the 
appointment with the research nurse in two weeks or later. Failure to complete these 
forms or attend this follow-up appointment resulted in exclusion from the study prior 
to randomization. 
At the follow-up visit with the re earch nurse (week 2) , the baseline data noted 
in sub ection 3.10.7 were recorded. In addition, the CCPT-II vvas administered at thi 
follow-up visit to establish a baseline score [42] . The CGI wa not completed at this 
follow-up appointment. The participant's psychiatrist also completed an enrolment 
form, including the baseline characteristics with as much redundancy as possible to 
ensure maximum accuracy of the data. The study did not require that the patients and 
their parent(s) or guardian(s) meet with the psychiatrist during their first follow-up 
visit. The res arch nurse conducted all subsequent measures of height , weight , blood 
pressure and pulse for consistency. The research nurse determined treatment assign-
ment according to the method outlined in section 3.6. The research nurse reviewed 
the schedule of survey administration with each participant and their parent(s) or 
guardian(s) and provided them with four 114 mL bottles of the syrup (4 x 114 mL 
bottles @ 5 mL/ day = an 88-day supply) and a follow-up appointment with their 
psychiatrist in eight weeks (week 10) . 
At each follow-up appointment following treatment initiation (weeks 10, 1 
and 26) , the research nurse measured the participant's height, weight, blood pressure 
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and pulse. At each follow-up visit, the nurse also measured the remaining syrup and 
conducted pill counts of other prescribed medications to estimate compliance. The 
psychiatrist completed a CGI scale at each visit . The participants completed the 
CCPT-II and a side-effects monitoring survey at each clinic visit. 
On weeks 10 and 18, the participants and their parent(s) or guardian(s) were 
provided with another four 114 mL bottles of the coded syrup and a follow-up appoint-
ment with their psychiatrist in eight weeks. At the week 18 clinic visit, the research 
nurse gave the participants and their parent(s) or guardian(s) another C3T and C3P, 
with instructions to complete them prior to their last clinic visit at week 26. The 
research nurse also phoned the participants and their parent(s) or guardian (s) during 
week 24 to remind them to complete the survey. The TSQ was repeated at the final 
clinic visit. Participants and theirparent(s) or guardian(s) had the opportunity to ask 
questions with any team member during these clinic visits. They vvere also instructed 
to contact the research nurse between visits with any questions . 
Perfect attendance at follow-up appointments was not compulsory to remain 
in the study. Study participants were contacted following missed appointments by 
the research nurse. They were ofiered another appointment and arrangements would 
have been made for a another supply of their assigned supplement. Unfortunately, all 
study participants that missed appointments chose to withdraw from the study when 
they were contacted by the research nurse. This is discussed further in section 4.3 and 
section 5.3. 
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3.12 Statistical Analysis 
3.12.1 Baseline Data 
Baseline data were compared using t tests for continuous variables, x2 and Fisher 's 
exact tests for categorical and nominal variables, and iann-Whitney U tests for rank 
and ordinal variables. 
3.12.2 Planned Analyses 
Planned group comparisons were performed on the primary and secondary outcome 
measure where possible. Data distributions were normal for the C3T [40] , the C3P [40] , 
CCPT-II [42] and CGI; therefore 2-tailed t t sts (p < .05) were used for these analyses. 
The TSQ produces non-parametric data requiring analysis using the Mann-Whitney 
U, 2-tailed tests (p < .05). An a priori decision was made to use the la t observation 
carried forward (LOCF) for missing data. 
The original intent W e to use multivariate analysi to asse the ffect of group 
assignment on the primary and secondary outcomes, controlling for potential covariates. 
These covariates were to include the d gree of omega-3 fatty acid insufficiency, as 
measured by the TSQ, number of comorbid diagnoses, age, gender, ADHD subtype, 
and baseline ADHD severity, as measured by the C3T, C3P and CCPT-II. It was 
not possible to onduct this analysis due to insufficient data. One patient per group 
completed the study r sulting in one completed pair of C3T and C3P per group. The 
C3T and C3P were each completed prior to the first and last clinic visits. This is 
discussed further in section 4.3 and section 5.3. 
All study data were collected in a password protected Microsoft Excel Spread-
sheet. Statistical analysis of study data was conducted in SPSS version 20. 
Chapter 4 
Results 
This was a pilot study intended to assess the feasibility of augment ing the t reatment 
of ADHD in children and adolescents with an omega-3 fatty acid supplement . Due 
to a high number of dropouts the study was not sufficiently powered to detect group 
differences. All values of the primary and secondary outcomes yielded p values greater 
than .05. T he values are not reported on a scale as this would imply meaning where 
none exists. Reporting specific values might leacl the reader to make inferences about 
the strength of associations, which are not appropriate. 
4 .1 Demographics 
4 .1.1 Age 
As displayed in Table 4.1 and Figure 4.1, t he mean ages of the active, placebo and 
combined groups were 13.3 (SD = 3.7), 12 (SD = 3.6) and 12.7 (SD = 4.0) respectively. 
An independent-samples t test was conducted to compare the mean age of active and 
placebo group part icipants . There was no significant difference in the mean age of 
30 
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active and placebo group participants; p > .05. This suggests the active and placebo 
groups were comparable in their mean ages. 
Table 4. 1: Age 
Ma SD Min. Max. Mdn 
Activeb 13.3 3.7 8.1 16.8 15.4 
Place bob 12.0 3.6 6.7 16.9 12.8 
Total 13.0 4.0 6. 7 16.9 13.5 
Nate. M = Mean. SD = Standard 
Deviation. Min. = Minimum. 
Max. = Maximum. Mdn = Median. 
a Active vs. P lacebo: p > .05. bn = 7 
4 .1. 2 Gender 
There was a nearly even distribution of males to females in the study groups, with 
43%, 57% and 50% males in the active, cont rol and combined groups respectively. A 
Pearson Chi-Square test was conducted to compare the proportions of male and female 
participants in the active and placebo groups. There vvas no significant difference 
in these proportions; p > .05. This suggests the active and placebo groups were 
comparable in their gender distributions. 
4 .1.3 ADHD Subtype 
Eighty-six percent of t he active group and 71% of the control group were diagnosed 
with the combined subtype of ADHD (Table 4.2) . Fourteen percent of each group were 
diagnosed with the inattent ive subtype, while none of the active group and 14% of 
the control group were diagnosed with the hyperactive/impulsive subtype. 
As noted in Table 4.2, the numbers and proportions of participants with inat-
tentive, hyperactive/ impulsive and combined subtypes of ADHD in the active and 
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placebo groups were compared. A Pearson Chi-Square test was conducted to compare 
the proportions of part icipants in active and placebo groups with each subtype of 
ADHD. There was no significant difference in these proport ions; p > .05. This sug-
gests the active and placebo groups were comparable in their distribut ion of ADHD 
subtypes. 
Table 4.2: Attention Deficit Hyperactivity Disorder Subtypes 
Sub-type Active Placebo Total 
n % n % N % 
Inattentive Type 1 14 1 14 2 14 
Hyperactive/Impulsive Type 0 0 1 7 1 7 
Combined Type 6 86 5 71 11 79 
Note. Pearson Chi-Square test: p > .05. 
4 .1.4 Comorb idities 
As noted in Table 4.3 and Figure 4.2, the numbers and types of comorbidities in the 
active and placebo groups were compared. Pearson Chi-Square tests were concluded 
to compare the proportions of participants in active and placebo groups with these 
comorbid diagnoses. There were no significant differences in these proportions; p > .05. 
This suggests the act ive and placebo groups were comparable in the rates of these 
comorbid diagnoses. 
A visual inspection of the distribution of the tot al number of comorbid diagnoses 
among study participants (Figure 4.2) suggested this variable may not be normally 
distributed. A Shapiro-vVilk Test of normality indicated this variable significantly 
deviates from a normal distribution; p < .05. This suggests that non-parametric 
analysis is necessary. 
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Table 4.3: Comorbidit ies 
Sub-type Active P lacebo Total 
n % n % N % 
Conduct Disorder 1 14 0 0 1 7 
Generalized Anxiety Disorder 3 43 3 43 6 43 
Learning Disability 1 14 0 0 1 7 
Obsessive Compulsive Disorder 2 29 2 29 4 29 
Opposit ional Defiant Disorder 1 14 2 29 3 21 
Social Anxiety Disorder 1 14 1 14 2 14 
Tourette Syndrome 0 0 1 14 1 7 
Note. Pearson Chi-Square tests: p > .05 . 
Participants had a median of 2.0 (NI = 2.0, SD = 2.1) and 0.0 (M = 1.3, 
SD = 1. 7) comorbidities in the active and placebo groups respectively, with a com-
bined median ?f 1.5 (M = 1.6, SD = 1.9) comorbidities. A Mann-Whitney U test 
was conducted to compare the median number of comorbid diagnoses among active 
and placebo group part icipants. There was no significant difference in the mean num-
ber of comorbid diagnoses between active and placebo group part icipants; p > .05. 
This suggests the active and placebo groups were comparable in t heir mean rates of 
comorbidity. 
In total, 8 (57%) of the study participants had at least one comorbid diagnosis, 
while 6 ( 43%) did not . A single-sample Chi-Square test did not identify any significant 
difference in the proport ions of study par t icipants with and without at least one 
comorbid diagnosis; p > .05. This suggests that the presence or absence of a comorbid 
diagnosis was approximately equally likely among study part icipants. 
To det ermine whether study participants had a median number of comorbid 
diagnoses greater than 1, a one-sample Wilcoxon Signed Rank Test was conducted 
to compare the median number of comorbid diagnoses to 1. T he combined group's 
median number of comorbid diagnoses (Mdn = 1.5, lVI = 1.6, SD = 1.9) was not 
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significantly different than 1; p > .05. This analysis was repeated, including only study 
participants with at least one comorbid diagnosis, to determine if the median number 
of comorbid diagnoses was greater than 1 in this subset. This subset 's median number 
of comorbid diagnoses (Mdn = 2.5 , M = 2.9, SD = 1.6) was significantly different than 
1; p < .05. This suggests a bimodal distribution of this variable, with a nearly equal 
likelihood of study participants having either no comorbidities or multiple comorbidi-
ties. Participants with a single comorbidity appear to be relatively underrepresented. 
The study population seemed to be heterogeneous in this regard, with approximately 
half the study participants having no additional diagnoses, while the remainder had 
multiple additional diagnoses, adding to their cumulative burden of illnesses. 
4.1.5 Number of Medications 
A visual inspection of the distribution of the total number of medications prescribed per 
study participant (Figure 4.3) suggested this variable may not be normally distributed. 
A Shapiro-Wilk Test of normality indicated this variable significantly deviates from a 
normal distribution; p < .05. This suggests t hat non-parametric analysis is necessary. 
Participants enrolled in the active group were prescribed a median of 1.0 (M = 
1.4, SD = 0.5) medications while those in the control group were prescribed a median 
of 2.0 (M = 1.9, SD = 0.9) medications. A Mann--Whitney U test was conducted to 
compare the median number of medications prescribed to part icipants in active and 
placebo groups. There was no significant difference in the mean number of medications 
prescribed to active and placebo group participants; p > .05. This suggests the active 
and placebo groups were comparable in the median number of medications prescribed. 
To determine whether study part icipants had a median number of prescribed 
medications greater than 1, which would otherwise be expected for uncomplicated 
ADHD [3, 4, 2] , a one-sample Wilcoxon Signed Rank Test was conduct ed to compare the 
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median number of prescribed medications to 1. Combined, participants were prescribed 
a median of 1.5 (M = 1.6, SD = 0.7) medications. This median number of medications 
prescribed was significantly greater than 1; p < .05. Study participants were therefore 
more likely to be prescribed addit ional medications. This finding could suggest a 
high level of ADHD severity among participants, or a high likelihood of comorbid 
diagnoses requiring additional medications. In either case, the prescription of addit ional 
medications suggests an addit ional burden of illness beyond uncomplicated ADHD , 
which would usually be treated with a single medication [3, 4, 2]. 
4.2 Baseline Characteristics 
4.2.1 ADHD Severity Measures 
There were 3 composite measures of ADHD severity derived from the data: t he CCPT-
CI, the C3T-T, and the C3P-T. Each measure was generated automatically as part 
of each standardized tool 's schedule of analysis, as discussed in the methods. Parents, 
guardians and teachers completed the C3P and C3T in every case that a participant 
returned for a follow-up appointment. No problems in completing these assessments 
were evident. 
4.2.1.1 Conners Continuous Performance Test II 
Four study participants did not complete their baseline CCPT-II prior to receiving their 
supplements. These baseline assessments were not completed because of an inability 
or unwillingness to complete t he entire assessment process. Incomplete assessments 
resulted in no data. These 4 participants had each been assigned to the active group 
but had not begun taking their supplement at the t ime of this initial assessment. 
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As displayed in Figure 4.4, the mean baseline CCPT-CI was 61.9 (SD = 24.1), 
52.3 (SD = 16.7), and 55.2 (SD = 18.4) in the active, placebo and combined groups 
respectively, with Confidence Index scores above 50% suggesting clinically significant 
symptoms of ADHD. An independent-samples t test was conduct d to compare the 
mean CCPT-CI scores by participants in active and placebo group . There was no 
significant difference in the mean scores for active and placebo group participants; 
p > .05. This suggests the active and placebo groups were comparable in their baseline 
ADHD symptom severity, as measured by the CCPT-CI. 
A single-sample two-sided t test was conducted to compare the mean CCPT-CI 
score by part icipants in t he combined group to t he "Clinically Significant ' cut-off score 
of 50%. The combined group's mean core (JV! = 55.2, SD = 18.4) was not significantly 
different than the "Clinically Significant" cut-off score of 50%; p > .05. This suggests 
the average severity of ADHD symptoms among study participants, as measured by 
the CCPT-CI: were clinically significant but not markedly so. 
4.2.1.2 Conners 3: Teacher Report 
As noted in Figure 4.5 and Table 4.4, the mean baseline C3T-T scores were 76.1 (SD = 
13.4), 74.6 (SD = 13.8) , and 75.4 (SD = 13.1) in the active, placebo and combined 
groups respectively. An independ nt-samples t test was conducted to compare the 
mean C3T-T scores by participants in active and placebo group . There was no 
significant difference in the mean scores for active and placebo group participants; 
p > .05. The remaining mean subtest scores in t he C3T did no differ significantly 
between the active and placebo group . This suggests the active and placebo groups 
were comparable in their mean baseline symptom severity, as reported by their teachers 
and measured by the C3T, including symptoms of ADHD and commonly associated 
Disruptive Behaviour Disorders. 
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Table 4.4: Conners 3: Teachers Report (Baseline) 
Sub-testa,b Activec P laceboc Totald,e 
M SD M SD M SD 
Inattention 72.9 15.4 67.6 10.7 70.2 1.5 
Hyperactivity / Impulsivity 72.3 19.2 69.6 15.6 70.9 1.3 
Learning Problems 63.4 13.4 62.6 9.8 63.0 -1.8 
Executive Functioning 63.1 13.9 66.1 10.1 64.6 -0.1 
Defiance/ Aggres ion 80.0 15.7 60.3 29.0 70.1 0.8 
Peer Relations 70.9 18.4 56.0 14.3 63.4 - 0.3 
ADHD (Inattentive Type) 69.3 17.3 66.7 11.1 68.0 0.8 
ADHD (Hyperactive-Impulsive Type) 72.6 19.4 68.6 16.7 70.6 1.2 
Conduct Disorder 69.0 13.5 56.6 9.8 62.8 -0.6 
Opposit ional Defiant Disorder 81.6 15.2 70.6 16.4 76.1 * 2.6 
Global Index: Restless-Impulsive 74.9 13.6 71.7 15.0 73.3* 2.2 
Global Index: Emotional Lability 71.7 16.0 71.1 17.2 71.4 1.5 
Global Index: Total 76.1 13.4 74.6 13.8 75.4* 3.0 
Note. M = Mean. SD = Standard Deviation. ascores < 65 are Average 
or Below; 65 - 69 are Elevated; 2: 70 are Very Elevated. 
bindependent-samples t test comparing mean group scores; all p > .05. 
en = 7. d N = 14. eSingle-sample t test of combined group scores versus 
65 cutoff score. * M > 65; p < .05. 
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A single-sample two-sided t test was conducted to compare the mean C3T-T 
score by participants in the combined group to the "Elevated" cut-off score of 65. The 
combined group 's mean total score (M = 75.4, SD = 13. 1) was significantly greater 
than the "Elevated" cut-off score of 65; p < .05. This suggests the average severity 
of ADHD symptoms among study participants, as reported by their teachers and 
measured by the C3T-T, was elevated and likely clinically significant. 
A single-sample two-sided t test was conducted to compare the mean C3T-T 
score by participants in the combined group to the "Very Elevated" cut-off score of 70. 
The combined group's mean total score (M = 75.4, SD = 13.1) was not significantly 
greater than the "Very Elevated" cut-off core of 70; p > .05. Thi suggests the average 
severity of ADHD symptoms among study participants, as reported by their teachers 
and measured by the C3T-T, was elevated but not markedly so. 
Singl -sample two-sided t t sts were conducted to compare the mean C3T 
subtest scores by participants in the combined group to the "Elevated" cut-off score 
of 65. The mean scores in the Oppositional Defiant Disorder (NI = 76.1 , SD = 16.2) 
and Global Index: Restless-Impulsive (lvf = 73.3, SD = 13.8) ub-tests were each 
significantly greater tha11 65; p < .05. The remaining subtests were not significantly 
different from th "Elevated" cut-off score of 65; p > .05. This suggests the average 
symptom severity of ADHD and commonly associated Disruptive Behaviour Disorders 
among study participants, as reported by their teachers and measured by the C3T 
subtests, wer elevated and likely clinically significant in several cases and did not 
exceed this threshold in other cases. 
4 .2.1.3 Conner s 3: Parent R eport 
As noted in Table 4.5 and Figure 4.6, th mean C3P-T scores were 79.9 (SD = 8.9) , 
89.6 (SD = 0. ), and 84.7 (SD = 7.9) in the active, placebo and combined groups 
CHAPTER 4. RESULTS 44 
respectively. An independent-samples t test was conducted to compare the mean C3P-
T scores by participants in active and placebo groups. There was a significant difference 
in the mean scores for active and placebo group participants; p < .05. This suggests 
that placebo group part icipants experienced significantly greater mean baseline ADHD 
symptom severity, as reported by their parent(s) and/ or guardians and measured by 
the C3P-T, than did active group participants. The remaining mean subtest scores 
in the C3P did not differ significantly between the active and placebo groups. This 
suggests that active and placebo group part icipants were otherwise comparable in 
their mean baseline symptom severity, as reported by their parent(s) and/or guardians 
and measured by the C3P subtests, including symptoms of ADHD and commonly 
associated Disruptive Behaviour Disorders. 
A single-sample two-sided t t est was conducted to compare the mean C3P-T 
score by participants in the combined group to the "Very Elevated" cut-off score of 
70. The combined group's mean total score (M = 84.7, SD = 7.9) was significantly 
greater than the "Very Elevated" cut-off score of 70; p < .05. This suggests the average 
severity of ADHD symptoms among .study participants, as reported by their parent(s) 
and/or guardians and measured by the C3P-T, was markedly elevated and clinically 
significant. 
Single-sample two-sided t tests were conducted to compare the mean C3P 
subtest scores by participants in the combined group to the "Very Elevated" cut-
off score of 70. The mean scores in 7 of the 12 remaining sub-tests (Inattent ion, 
Hyperactivity/Impulsivity, Defiance/ Aggression, ADHD (Inattentive Type), ADHD 
(Hyperactive-Impulsive Type) , Oppositional Defiant Disorder and Global Index: Emo-
tional Lability) were significant ly greater than 70; p < .05. The mean scores of an 
additional 2 sub-tests (Executive Functioning and Global Index: Restless-Impulsive) 
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Table 4.5: Conners 3: Parent Report (Baseline) 
Sub-testa,b Activec Placeboc Totald,e 
M SD M SD M SD 
Inattention 76.6 9.6 81.1 8.7 78.9*** 9.1 
Hyperactivity / Impulsivity 78.1 10.7 87.0 7.5 82.6*** 10.0 
Learning Problems 67.0 15.2 62.9 13.9 64.9 14.2 
Executive Functioning 74.3 11 .3 75.4 11.8 74.9** 11.1 
Defiance/ Aggression 73.6 18.0 85.9 8.6 79. 7*** 15.0 
Peer Relations 66.7 17.8 73. 1 18.5 69.9 17.8 
ADHD (Inattentive Type) 78.6 11.0 77.6 10.2 78.1 *** 10.2 
ADHD (Hyperactive-Impulsive Type) 76.7 11.0 87.0 7.5 81.9*** 10.5 
Conduct Disorder 68.1 17.0 76.6 13.5 72.4 15.3 
Opposit ional Defiant Disorder 74.3 14.4 81.9 8.9 78.1 *** 12.1 
Global Index: Restless-Impulsive 80.1 10.7 86.6 5.2 83.4** 8.7 
Global Index: Emotional Lability 71.6 6.9 81.9 11.7 76. 7*** 10.7 
Global Index: Total* 79.9 8.9 89.6 0.8 84.7*** 7.9 
Nate. M = Mean. SD = Standard Deviation. ascores < 65 are Average 
or Below; 65 - 69 are Elevated; ;:::: 70 are Very Elevated . 
bindependent-samples t test comparing mean group scores. en = 7. 
d N = 14. eSingle-sample t test of combined group scores versus 65 and 
70 cutoff scores. *Active -::f. Placebo; p < .05. ** M > 65; p < .05. 
*** j\1[ > 70; p < .05. 
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were significantly greater than the "Elevated" cut-off score of 65; p < .05. The re-
maining subtests (Learning Problems, Peer Relations and Conduct Disorder) were not 
significantly different from t he "Elevated" cut-off score of 65 ; p > .05. This suggests the 
average symptom severity of ADHD and commonly associated Disruptive Behaviour 
Disorders among study participants, as reported by their parent(s) and/or guardians 
and measured by the C3T subtests, were elevated and likely clinically significant in 
several cases and did not exceed this threshold in other cases. 
4 .2.1.4 Conners 3: Teacher and Parent R eports Compare d 
The C3T and C3P include the same sub-tests and the same standardized scoring 
system. The teacher and parent mean baseline sub-test scores were compared using 
two-sided paired t tests. The active and _placebo groups wer combined for these 
baseline comparisons. 
The Parent report scores were consistently higher in each subtest , with differ-
ences ranging from 1.9 to 11 .6 (t-score) (Table 4.6 & Figure 4.7) . Seven of the 13 
ub-tests (Inattention, Hyperactivity / Impulsivity, Executive Functioning, ADHD (Inat-
tentive Type), ADHD (Hyperactive-Impulsive Type), Global Index: Restless-Impulsive, 
Global Index: Total) were significantly different; p < .05. This suggests that , in some 
cases, study participant parent(s) and/or guardians reported significantly higher symp-
tom severity of ADHD and commonly associated Disruptive Behaviour Disorders than 
did their teachers, while in other cases, th ir reporting of symptom severity was com-
parable. 
4 .2 .2 Signs of Omega- 3 Fatty Acid D eficiency 
Approximately half of each group \Vere omega- 3 deficient according to t he init ial TSQ 
(Appendix C) , with total scores greater than or equal to 4. A Pearson Chi-Square 
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Table 4.6: Baseline Conners 3: Teacher and Parent Reports Compared 
Sub-testa Teacherb Parentb n c 
M SD M SD 
Inattention 70.2 13.0 78.9 9. 1 8.7* 
Hyperactivity / Impulsivity 70.9 16.9 82.6 10.0 11.6* 
Learning Problems 63.0 11.3 64.9 14.2 1.9 
Executive Functioning 64.6 11.8 74.9 11.1 10.2* 
Defiance/ Aggression 70.1 24.6 79.7 15.0 9.6 
Peer Relations 63.4 17.6 69:9 17.8 6.5 
ADHD (Ina t tentive Type) 68.0 14.0 78.1 10.2 10.1 * 
ADHD (Hyperactive-Impulsive Type) 70.6 17.5 81.9 10.5 11.3* 
Conduct Disorder 62. 13.1 72.4 15.3 9.6 
Opposicional Defiant Disorder 76.1 16.2 7 .1 12.1 2.0 
Global Index: Restless-Impulsive 73.3 13.8 83.4 8.7 10.1* 
Global Index: Emotional Lability 71 .4 15.9 76.7 10.7 5.3 
Global Index: Total 75 .4 13.1 84.7 7.9 9.3* 
Nate . M = Mean. SD = Standard Deviation. 
D = Mean Parent- Teacher sub-test scores. 
as cores < 65 are Average or Below; 65 - 69 are Elevated ; 
~ 70 are Very Elevated. b Active and Placebo groups combined. 
crndependent-samples t test comparing mean group scores. 
* p < .05. 
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test was conducted to compare the proportions of participants in active and placebo 
groups with initial TSQ total scores :2: 4. There was no significant difference in the 
proportions of active group participants (n = 4, 57%) and placebo group participants 
with total scores greater than or equal to 4 (n = 3, 43%); p > .05. This suggests the 
active and placebo groups were comparable in the prevalence of baseline omega-3 
fatty acid deficiency, as measured by the TSQ. 
A Mann-Whitney U test was conducted to compare the median initial TSQ 
scores among active and placebo group participants (Table 4. 7). There was no sig-
nificant difference in the median initial TSQ scores in the active group participants 
(Mdn = 6.0, M = 5.6, SD = 4.4) and the placebo group participants (Mdn = 3.0, 
J\11 = 3.7, SD = 3.5), p > .05. This suggests the active and placebo groups were 
comparable in median degree of baseline omega-3 fatty acid deficiency, as measured 
by the TSQ. 
Table 4.7: Thirst-Skin Questionnaire Initial Responses 
Specific Symp omsa Activeb Place bob To talc 
M Mdn SD M Mdn SD M Mdn SD 
Brittle Nails 0.6 0.0 1.0 0.6 0.0 1.0 0.6 0.0 0.9 
Bumps 1.0 0.0 1.4 1.1 1.0 1.3 1.1 0.5 1.3 
Dandruff 0.3 0.0 0.5 0.1 0.0 0.4 0.2 0.0 0.4 
Dry Hair 0.3 0.0 0.5 0.1 0.0 0.4 0.2 0.0 0.4 
Dry Skin 0.9 0.0 1.2 0.1 0.0 0.4 0.5 0.0 0.9 
Excessive Thirst 2.1 3.0 1.2 1.3 1.0 1.4 1.7 2.0 1.3 
Frequently Urinates 1.0 0.0 1.3 0.9 0.0 1.5 0.9 0.0 1.3 
Total Scored 5.6 6.0 4.4 3.7 3.0 3.5 4.6 3.5 3.9 
Note. M = Mean. Mdn = Median. SD = Standard Deviation. 
a Mann-\tVhitney U tests comparing group median TSQ scores; 
all p > .05. bn = 7. c N = 14. 
dScores :2: 4 indicate Omega-3 fatty acid deficiency. 
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Mann-Whitney U tests were conducted to compare the median scores for each 
symptom on the initial TSQ symptoms among active and placebo group participants. 
There were no significant differences in these median initial scores for each symptom 
among the active group participants and the placebo group participants; p > .05. This 
suggests the active and placebo groups were comparable in the baseline prevalence 
of specific symptoms suggestive of omega-3 fatty acid deficiency, as measured by the 
TSQ. 
A single-sample two-sided Wilcoxon signed rank test was conducted to evaluate 
whether the median initial TSQ total score for the total study population was signifi-
cantly different than 4. The median of the initial TSQ total score for the total study 
population was 3.5 (M = 4.6, SD = 3.9). The results did not indicate a significant 
difference, p > .05 . This suggests the median baseline degree of omega-3 fatty acid 
deficiency clicl not exceed the clinically significant threshold , with a TSQ total score 
greater than 4. 
4.3 Study Completion 
Five (71 %) of the active group participants and 3 ( 43%) of the placebo group par-
tkipants did not return for the first check-in following treatment assignment at 10 
weeks (Table 4.8) . Another 1 (14%) of the active group participants and 3 ( 43%) of 
the placebo group participants did not return for the second check-in at 18 weeks. One 
study participant per group returned for the 18 and 26 week visits, completing the 
study (14%). Active group participants remained in the study for a mean of 6.4 weeks 
(SD = 9.2) while placebo group participants withdrew after an average of 8.8 weeks 
(SD = 8.4) . 
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Table 4.8: Study Completion 
·w eek Descript ion Active Placebo 
n % n % 
0 Study introduction visit 7 100 7 100 
2 Treatment initiation 7 100 7 100 
10 Follow-up visit 1 2 29 4 57 
18 Follow-up visit 2 1 14 1 14 
26 Study Completion 1 14 1 14 
Note. n = 1 umber of participants returning. 
%= Percentage of group. 
A Kaplan-Meier survival analysis (log-rank test) was conducted to compare 
study wit hdrawal by participants in active and placebo groups. There was no significant 
difference in the survival curves between active and placebo group participants; p > .05. 
This suggests the active and placebo group were comparable in regard to study 
completion. 
A Kaplan-Meier survival analysis (log-rank test) was conducted to compare 
study withdrawal by participants with and without comorbid diagno es. T here was 
a significant difference in the survival curves between participants with and without 
comorbid diagnoses; p < .05. This suggests that study participants with comorbid 
diagnoses were significantly more likely to prematurely withdraw from the study. 
4 .3.1 Reasons for Withdrawal 
Two participants (33%) in each treatment group cited the taste/aftertaste of the 
supplement as the reason for study withdrawal (Table 4.9). One (17%) participant in 
the active group and 2 (33%) in the placebo group listed gastrointestinal complaints, 
including heartburn, cramps and stomach upset, as their reasons for study withdrawal. 
One active group participant (17%) developed a fish allergy and had to withdraw. 1 
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participant from each group (17%) withdrew for undisclosed reason , cited as unrelated 
to the study. One placebo group participant (17%) withdrew complaining of lack of 
efficacy of t he supplement. An active group participant (17%) withdrew fearing side-
effects, noting they had not actually experienced any adverse-effe .ts. 
Table 4.9: Reasons for withdrawal from study 
Reasona,b Active Placebo 
n % n % 
Taste/ Aftertaste 2 33 2 33 
Gastrointestinal Complaints 1 17 2 33 
Developed Fish Allergy 1 17 0 0 
Factors Unrelated to Study 1 17 1 17 
Lack of Efficacy 0 0 1 17 
Fear of side effects 1 17 0 0 
Note. n = l umber of participants. 
% = Percentage of group. aFisher's exact test 
comparing frequency of reasons for study 
withdrawal. bAll p > .05. 
Fisher's Exact Tests were conducted to compare the frequency of reasons for 
stud·y withdrawal recorded by participants in active and ·placebo groups. There were 
no significant differences in the frequency of reasons for study withdrawal between 
active and placebo group participants, p > .05. This suggests the active and placebo 
group participants were comparable in their reasons for withdrawal. 
4 .3.2 Cox Proportional Hazards Regression 
A Cox Proportional Hazards Regression was conducted on several variables to assess 
their effect on study withdrawal (Tabl 4.10). The variables included in the regression 
model were: the treatment assignment group, the number of comorbidities, the number 
of medication prescribed, and 3 baseline measures of ADHD severity (the CCPT-CI, 
the C3T-T and the C3P-T ). The variables were entered in a single block, using the 
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::Enter" method in SPSS. one of the variables yielded an Exp(B) with a p < .05. The 
regression was repeated using a variety of permutations of removing various variables 
and using multiple blocks and methods of variable entry, with no meaningful change 
from the initial outcome. The process was repeated using the presence/absence of 
comorbidities rather than the number of comorbidities in light of the significant result 
in t he Kaplan-Meier survival analysis (section 4.3). There was no meaningful change 
to the Cox Proportional Hazards Regression analysis as a result. Linear Regression 
analysis similarly yielded no significant relationships between these variables and 
time in study; p > .05. This suggests these baseline measures of ADHD symptom 
severity, treatment group assignment , and the number of comorbidities and medications 
prescribed did not have a significant effect on study withdrawal. 
Table 4.10: Cox Proportional Hazards Regression Analysis of Factors Affecting Study 
Withdrawal 
Variable 
Number of Cormorbidities 
Conners Continuous Performance Test II Confidence Index 
Conners 3: Teachers Report Global Index: Total 
Conners 3: Parent Report Global Index: Total 
umber of Medications Prescribed 
Active Group Assignment 
Note. a All p > .05 
4 .3.3 Tolerability/ Adverse Effects 
Exp(Bl 
0.612 
0.948 
1.130 
1.294 
2.557 
39.465 
Two study participants in the active group and 4 in the placebo group completed at 
least one AEI (Appendix B, Table 4.11). 
A Shapiro-vVilk Test of normality indicated the number of adverse effects experi-
enced by participants does not significantly deviate from a normal distribution; p > .05. 
This suggests that parametric methods can be employed. An independent-samples 
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Table 4.11: Adverse Effects 
Adverse Effect Activea Place bob 
Belching 
Nausea 
Diarrhoea 
Bloating 
Gas 
Fishy Body Odour 
Fish Breath 
Fishy Aftertaste 
n 
0 
0 
0 
0 
0 
0 
2 
1 
% n 
0 3 
0 3 
0 3 
0 2 
0 2 
0 1 
100 0 
50 2 
Note. n = Number of respondents 
experiencing adverse effects. 
% = Percentage of respondents 
experiencing adverse effects. 
an= 2. b n = 4. 
% 
75 
75 
75 
50 
50 
25 
0 
50 
55 
t test was conducted to compare the mean number of adverse effects experienced 
by active and placebo group participants. There was no significant difference in the 
mean number of adverse effects experienced by active group part icipants (M = 1.5, 
SD = 0.7) and placebo group participants (M = 4.3, SD = 2. 1); p > .05. This suggests 
t he active and placebo groups were comparable in their mean numb er of adverse effects 
reported . 
Fisher 's Exact Tests were conducted to compare the occurrence of specific 
adverse effects experienced by part icipants in active and placebo groups. There were 
no significant differences in the occurrence of specific adverse effects between active 
and placebo group part icipants; p > .05. This suggests the active and placebo groups 
were comparable in t he rates of specific adverse effects. 
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4 .3.4 Compliance 
Although the number of study participants returning for follow-up visits was too small 
to permit statist ical analysis of t he data, compliance with omega-3 supplements and 
prescribed medications was comparable between the active and placebo supplements, 
and between the omega-3 supplements and prescribed medications. 
4.4 Outcomes 
Several of the planned analyses could not be conducted as only one study part icipant 
per t reatment group completed the trial, including the Conners 3 Parent and Teacher 
Reports, which were only administered at the beginning and end of the trial. The 
remaining ineasures were repeated at each clinic visit throughout the trial. Analysis 
of single values per treatment group would not be meaningful, so study outcomes 
were analyzed using an LOCF approach . T he use of before and after measurements 
in the analysis meant that only observations from participants with at least one post-
t reatment assessment could be included in t he analysis. 
An LOCF analysis was conducted rather than other approaches for handling 
missing data for several reasons. Analysis of only subjects t hat completed the t rial 
would be of limited value. Other means of imputat ion, including regression-based 
statistical models were not possible with the limited sample size. 
4.4.1 ADHD Severity Measures 
4.4.1.1 Conners Continuous Performance Test II 
As noted in subsubsection 4.2.1.1, 1 of the 4 study participants that did not complete 
their baseline CCPT-II prior to receiving their supplements was able to complete these 
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assessments later in the course of his/her participation. This data was included in 
the comparison of initial and final scores, with the last observation carried forward. 
This data was included to permit analysis of this variable. Without inclusion of these 
observations, comparison of the change in ADHD symptom severity, as measured by 
the CCPT-II, would not have been possible. This analysis is included for the purposes 
of generating hypotheses and assessing the data analysis process as part of the larger 
goal of establishing the feasibility of and refining the protocol for a larger study. No 
inferences regarding the efficacy of the supplement being studied are intended. 
Two participants from the active treatment group and 4 from the control group 
were included in this analysis of CCPT-CI [42] (Table 4.12 and Figure 4.8). 
Table 4.12: Conners Continuou Performance Test II Confidence Index 
Active Placebo 
n M SD n M SD 
First Recordeda 3 58.0 21.2 7 52 .3 16.7 
First Recorded (Censored )a,b 2 40.3 8.1 4 48.7 21.1 
Last Recordeda 2 31.4 26.3 4 56.5 24.7 
Delta a 2 - 8.9 18.2 4 7.8 17.0 
Note. M =Mean Confidence Index(%). Scores above 50% are 
suggestive of ADHD. SD = Standard Deviation . 
arndependent-samples t test comparing mean group scores; 
all p > .05. bSubjects with only initial observations removed. 
An independent-samples t test was conducted to compare the change in scores 
on the CCPT-CI in active and placebo groups. There was no significant difference 
in the change in scores for active group participants (M = -8.9, SD = 18.2) and 
placebo group participants (M = 7.8, SD = 17.0); p > .05. This suggests the active 
and placebo groups were comparable in the change in ADHD symptom severity, as 
measured by the CCPT-CI. 
CHAPTER 4. RESULTS 
100~---------r------------------------------~ 
-
so-
60-u 
I <D 
legend 
I First: Uncensored 
I First: Censored 
Last 
t 
u 
u 
( D Scores above 50% are suggestive of ADHD 
u 
'*-1.1'1 
0'1 40-
20-
-----------------------------<~ - --------
<I> 
0~--------~--------------------~.r-------~ 
Active Placebo 
58 
Figure 4.8: Mean Conners Continuous Performance Test II: Confidence Index (CCPT-
CI) Results (95% Confidence Intervals): First and Last Observations 
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The initial and final scores in each group were not significantly different from 
the cut-off score of 50% using single-sample two-sided t tests; p > .05. This suggests 
that both the init ial and final scores were not markedly greater than the 50% cut-off 
score, indicating clinically significant ADHD symptom severity. 
4 .4.1.2 Conners 3: Teachers and Parent Reports 
As noted in section 4.4 and section 5.4, 1 participant in each group completed the t rial 
and Conners 3: Teachers and Parent Reports. Statistical comparison was therefore not 
possible. 
4.4.2 Clinical Global Impression Scale 
Two active group participants and 4 placebo group participants were assessed by their 
psychiatrist via the CGI Scale at least once (Table 4.13, Figure 4.9 and Appendix A). 
The last available CGI scores were used for each participant in the planned LOCF 
comparisons. 
Table 4.13: Clinical Global Impression Scale (Last Observation Carried Forward) 
Scalea Activeb Placeboc 
M SD M SD 
Severity of Illnessd 3.5 0.7 2.5 1.0 
Global Improvemente 3.0 0.0 3.3 1.0 
Efficac/ 9.5 0.7 9.5 5.2 
Nate. M = Mean. SD = Standard Deviation. 
arndependent-samples t t est comparing mean 
group scores; all p > .05. b n = 2. c n = 4. 
d1, :'\ot at all ill - 7, Extremely ill. e1, Very 
much improved - 7, Very much worse. 
f1 , Marked improvement , No side effects - 16, 
Unchanged or worse, Side effects outweigh 
therapeutic effects. 
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CHAPTER 4. RESULTS 61 
An independent-samples t t est was conducted to compare scores on the Severity 
of Illness scale in the active and placebo groups. There was no significant difference 
in the scores for active group participants (M = 3.5 , SD = 0. 7) and placebo group 
participants (M = 2.5, SD = 1.0) ; p > .05. A score of 3.5 on this scale is between 
"mildly and moderately ill", while a score of2.5 is between "borderline mentally ill" and 
"mildly mentally ill". This suggests the active and placebo groups were comparable in 
their last observed severity of illness, as measured by the CGI. 
An independent-samples t test was conducted to compare scores on the Global 
Improvement scale in the active and placebo groups. There was no significant difference 
in t he scores for active group participants (M = 3.0, SD = 0.0) and placebo group 
participants (iv1 = 3.3, SD = 1.0) ; p > .05. A score of 3.0 on this scale is "minimally 
improved", while a score of 3.3 is between this and "no change". This suggests the 
. . 
active and placebo groups were comparable in their overall improvement, as measured 
by t he CGI. 
An independent-samples t test was conducted to compare scores on the Efficacy 
scale in the active and placebo groups. There was no significant difference in the scores 
for active group participants (1\II = 9.5, SD = 0.7) and placebo group participants 
(M = 9.5, SD = 5.2); p > .05. A score of 9 corresponds t o "Minimal" therapeutic effect 
and no side effects, while a score of 10 corresponds to the same "Minimal" therapeutic 
effect and side effects that ''do not interfere with patient's functioning". This suggests 
the active and placebo supplements were comparable in their last observed efficacy, 
with minimal therapeutic and adverse effects, as measured by the CGI. 
4.4.3 Signs of Omega- 3 Fatty Acid Deficiency 
One active group participant and 2 placebo group participants completed a second 
TSQ (Figure 4.10 and Appendix C). 
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Figure 4.10: Mean Thirst Skin Questionnaire (TSQ) Scores: First and Last Observa-
tions (95% Confidence Intervals) 
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A Mann-Whitney U test was conducted to evaluate the hypothesis t hat par-
ticipants in the active group would experience a greater decrease in Total Score, on 
average, than placebo group participants on the TSQ. The was no significant difference 
in the median changes in the TSQ scores for the active and placebo groups, p > .05. 
The active group participant had a decrease in total score of 1.0, while t he placebo 
group participants had a median decrease in total score of 2.5 (!VI= 2.5, SD = 2.1). 
This suggests the active and placebo supplements were comparable in their effect on 
the degree of omega- 3 fatty acid deficiency, as measured by the TSQ. 
Chapter 5 
Discussion 
5.1 D emographics 
5.1.1 A ge 
As discussed in subsection 4.1.1, the mean age, age range and median ages were typical 
of this clinical population, both locally and abroad [1, 2, 4]. 
5.1.2 Gender 
As described in subsection 4.1.2, the nearly 1:1 gender ratio is unusual as reported 
gender ratios typically range from 3:1 to 5:1 [1, 2, 4]. This difference could be due to 
the small sample size. It is possibly attributable to the referral source for this study; as 
a tertiary sub-specialty clinic, the clinic population would not necessarily be identical 
to that in the general population. Also, the inclusion and exclusion criteria may have 
resulted in a study population not reflecting the gender ratio found in the general 
population. T his is particularly likely as comorbid disruptive behaviour disorders, 
64 
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which are highly comorbid with ADHD and also overrepresented in males [1, 2, 4], 
were initially excluded from the study. This difference could also suggest a referral bias 
towards females or an unknown factor making it more likely for females than males 
in this population to participate in this study, although there is nothing to support 
either possibility. 
5.1.3 A DHD Subtype 
The distribution of ADHD subtypes among the groups and study population as a whole 
was similar, with the minor variation being most likely attributable to random variation 
and small sample size (subsection 4.1.3). There is little information available regarding 
the proportions of ADHD subtypes within non-clinical and clinical populations [1, 2, 4]. 
Anecdotally, this distribution of the majority of cases being of the combined subtype, 
with a roughly equal number of inattentive and hyperactive/impulsive subtypes, seems 
reflective of the distribution in general clinical practice. As discussed in subsection 1.3.1: 
there is no evidence that omega-3 fatty acid supplements are more or less efficacious 
depending on ADHD subtype. 
5.1.4 Comorbidities 
The frequency and types of comorbidities in each group were comparable (Table 4.3, 
subsection 4.1.4). These comorbid diagnoses and the percentage of participants with 
these diagnoses are comparable to reported rates [1, 2, 4]. Anecdotally, this is in 
keeping with this clinic's general population, which served as the referral base for this 
study. 
Comorbidity is common among patients with ADHD from clinical popula-
tions [1, 2, 4]. However, there is a paucity of published information concerning the 
total number of comorbidities typical per patient with ADHD from clinical populations, 
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or in general. Additional comorbidities likely confer a greater burden of illness, result-
ing in greater cumulative dysfunction with more comorbidities. It is unclear whether 
this cumulative effect of comorbid illnesses is addit ive or multiplicative, synergistically 
resulting in additional dysfunction. 
The proportions of study participants with and without comorbid diagnoses 
were not significantly different; t hese proportions are comparable to reported rates [1, 
2, 4]. 
The median number of comorbidities per study part icipant (Mdn = 1.5, NI = 
1.6, SD = 1.9) was not significantly different than 1. This suggests the level of co-
morbidity in this study population is at least as great as that seen in typical clinical 
populations. The median was trending towards an average of more than one comorbid-
. ity per participant . It is unclear whether this lack of a significant difference represents 
the true nature of this population, or if it is due to the small sample size. This study 
population was therefore likely experiencing considerable challenges, living with ADHD 
and most often one or more comorbidit ies. 
In a separa te analysis of study participants .with at least one comorbid diag-
nosis, the median total number of comorbidit ies per study part icipant (Mdn = 2.5, 
M = 2.9, SD = 1.6) was significantly greater than 1. This suggests a bimodal distri-
bution of comorbidity, whereby these study participants were equally likely to have 
comorbid diagnoses or not , but if they were diagnosed with comorbid illnesses, they 
were significant ly more likely than not to have more than one comorbid diagnosis 
(Figure 4.2) . 
5.1.5 Number of Medications 
Both treatment groups were prescribed a comparable median number of medications, 
with no significant difference between these medians (subsection 4. 1.5). The median 
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number of medications prescribed to the entire study population (Mdn = 1.5, M = 1.6, 
SD = 0.9) is significantly greater than 1. This is anecdotally comparable to the clinic 
population from which the study population is derived. T here is little published on 
the subject of the number of medications which patients with ADHD are typically 
prescribed in clinical or general populations. Treatment guidelines generally advocate 
for monotherapy for uncomplicated ADHD [45, 2, 3]. 
The prescription of more than one medication to the majority study partici-
pants seems compatible with the earlier finding that many study part icipants were 
diagnosed with one or more comorbid illnesses, with these additional medications 
possibly prescribed for these comorbid illnesses. This prescribing practice could also 
suggest suboptimal response to monotherapy in the treatment of their ADHD, which 
is sometimes the case with complex, treatment refractory cases of ADHD [45, 2, 3]. 
An analysis of the number of medications prescribed for ADHD versus comor-
bidities was not conducted because many medications that are prescribed for patients 
with one or more comorbidities often are effective in the treatment of more than one 
condition. Clonidine is a common example of this. It is prescribed to treat both ADHD 
and tic disorders, which are common comorbidities [45, 2, 3]. 
5.2 Baseline Characteristics 
5.2.1 ADHD Severity Measures 
5.2.1.1 Conners Continuous Performance T est II Confidence Index 
The mean CCPT-CI scores were not significantly different between groups (subsub-
section 4.2.1.1). The mean scores were all above the cutoff score of 50% but not 
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significantly so (Figure 4.4). In a treatment naive patient or group, this would sug-
gest a modest elevation in symptoms and relatively mild severity of impairment with 
ADHD. In the study participants, which were all prescribed stable treatment for their 
ADHD, these average scores likely indicate clinically significant residual symptomatol-
ogy. Another factor to consider is that the CCPT-CI is a composite score, meaning 
it can be affected by sub-test scores that markedly differ from the remaining scores, 
affecting the resulting composite scores accordingly. However, the CCPT-II is a robust, 
well validated assessment and research tool with sub-tests that account for these cir-
cumstances and provide measures of overall test validity that can help guide clinicians 
and researchers in the interpretation of these results [42]. The CCPT-II, including the 
CCPT-CI was considered valid in the results that were included for analysis. The small 
sample size could also have played a part, resulting in a non-representative sample, or 
a masked trend. 
5.2.1.2 Conners 3: Teacher and Parent Reports 
While the mean CCPT-CI scores [42] were mildly elevated, the mean C3T-T and C3P-
T scores were in the "Very Elevated " range (Table 4.4, Table 4.5, Figure 4.5, Table 4.6, 
Figure 4.6, & Figure 4. 7) , which is the highest severity level assigned by this instrument, 
and is assigned to T-scores 2:: 70 (subsubsection 4.2.1.2, subsubsection 4.2.1.3 and 
subsubsection 4.2.1.4) [40] . The guidelines for interpretation describe this group as 
having, "many more concerns than are typically reported" [40]. The mean C3P-T score 
was significantly above the "very elevated" cutoff score of 70, while the mean C3T-T 
was significantly above the "elevated " cutoff score of 65 but not 70. Nine of the 12 
remaining C3P subtests were significantly greater than the "elevated" cutoff, with 2 
significantly greater than the "very elevated" cutoff, while 2 of the 12 remaining C3T 
subtests were significantly greater than the "elevated" cutoff. 
CHAPTER 5. DISCUSSION 69 
It is unlikely t hese mean scores are art ificially elevated and represent bias on the 
part of the raters for several reasons. The C3T and C3P are robust, well constructed 
and validated tools that are designed to detect exaggeration and over-endorcement [40]. 
The assessment reports did not detect any invalid response patterns. The assessments 
were completed by different parents and teachers, which would lessen the likelihood of 
this pattern of elevating these scores out of keeping with the objective CCPT-II [42], 
unless this suggests a consistent bias in the population. 
vVhile it is possible the CCPT-II and the C3T and C3P rate ADHD severity 
differently, this is unlikely as these tools are constructed and marketed by the same 
group, use the same language and categories, and are intended to complement each 
other [40, 42] . 
. These results suggest the CCPT-II and the C3T and C3P, while valid and 
complementary, are sensitive to different aspects of ADHD symptomatology. The 
symptoms that improve the most readily and noticeably seem to be preferentially 
captured by the CCPT-II . The C3T and C3P are known to be better measures of 
executive function, particularly in real-world, longitudinal .settings [40]. 
The mean scores on the C3T and C3P suggest the study participants (both 
active and placebo groups) were experiencing considerable residual symptomatology 
in association with their ADHD in spite of stable treatment. In most cases, patients 
with ADHD achieve stable treatment when they have reached their maximum toler-
able medication dosage or have achieved satisfactory relief of symptoms [3, 2]. This 
discrepancy may be accounted for by a possible difference in sensitivity to aspects of 
ADHD symptomatology between the parents, teachers and clinicians, similar to the 
proposed difference between the C3P and C3T, and the CCPT-II. 
Mean C3T scores were consistently greater than C3P scores, including the 
Global Index: Total and all subtests (Table 4.6 & Figure 4. 7) . Seven of these 13 
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differences were st atistically significant, including the Global Index: Total score. This 
finding suggests that parents generally rat e their children 's symptomatology higher 
than do teachers. Parents may be more sensit ive to their children's difficult ies. Parent s 
are more likely to see their children without the benefit of stimulant medicat ions, 
both in the morning and the evening, prior to stimulant administration and following 
withdrawal from these stimulants. Conversely, teachers may have a broader perspective 
with which to rate a child 's symptomatology. Children may perform differently in 
different contexts and environments, which could also account for these differences. 
5.2.1.3 Comparison t o Related R esearch 
The severity of ADHD among study participants is comparable to t hat among similar 
studies [8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24]. As discussed in 
subsect ion 1.1.4, these symptom levels are also comparable to clinical populations, in 
keeping wit h the considerable residual ADHD symptomatology in spite of maximal 
therapies [1, 2, 3, 4]. 
5.2.2 Signs of Omega-3 Fatty Acid Deficiency 
As discussed in subsection 4.2.2, the median TSQ scores for the active and placebo 
groups were not significantly different , nor were the propor tion of each group wit h 
scores greater than or equal to 4. 
The median TSQ scores and the proportion of each group with total scores 
greater t han or equal to 4, indicating omega- 3 fatty acid deficiency (Table 4. 7) are 
consistent wit h other studies using this scale in similar populations [29, 31, 32, 22, 30] . 
The combined group's median TSQ score was not significantly different than 
4, although the mean score was greater than 4 (M = 4.6, SD = 3.9) . This may be 
due to the nonparametric distribut ion , small sample size and large standard deviation. 
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This could also be attributed to a high degree of variability of omega-3 status in the 
study and clinical population. The study and clinic population may have a mild to 
moderate degree of omega-3 deficiency. This could be connected to a higher t han 
expected intake of foods rich in omega-3 fatty acids, including t he growing number of 
foods that are enriched with these supplements without parents or children necessarily 
recognizing this. The clinic population is also derived from a culture with a traditional 
diet that is rich in fish, although it is unclear whether this reflects the current typical 
diet of this population. 
5.3 Study Completion 
The dropout ra te among both t reatment groups was high (section 4.3) . T here is 
no single obvious explanation for this outcome but many factors, including study 
design and participant charact eristics may have contributed to it. Some possible study 
design related factors include the length of the study, the inter-visit duration, inter-
visit follow-up, and the tolerability of the supplement/ placebo. Possible participant 
characteristics contributing to the high dropout rate include the severity of participant 
ADHD, the burden of comorbid diagnoses, and caregiver factors. These possible factors 
are explored in this section. Study protocol refinements to address t hese problems 
with study completion in addition to other deficits are outlined in section 6.5. 
5.3.1 Comparison to Similar Studies 
A recent Cochrane review of randomized clinical trials of polyunsaturated fatty acids 
(PUFAs) for ADHD in children and adolescents [7] assessed loss to follow-up among its 
outcomes (Table 5.1) . This analysis included 7 clinical trials [16, 18, 23, 24, 17, 39, 22] 
with a total of 589 participants, 34 7 receiving PUFAs and 242 receiving placebo. 
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Seventy-seven participants receiving PUFAs (22%) and 52 receiving placebo (21 %) 
were lost to follow-up . The percentage of participants lost to follow-up did not differ by 
treatment assignment; x2 (1, N = 589) = 2.77, p = .100. The percentage of participants 
lost to follow-up among these studies ranged from 0% [16] to 34% [22], with a mean 
loss to follow-up of 22%. 
Table 5. 1: Comparison of Loss to Follow-up Among Polyunsaturated Fatty Acids 
versus Placebo Clinical Trials 
Study Active Placebo Total Med. Suppl. LOS 
n N % n N % n N % 
Hirayama 2004 0 20 0 0 20 0 0 40 0 y EF 8 
Johnson 2009 3 37 8 8 38 21 11 75 15 N c 24 
Manor 2011 37 137 27 16 63 25 53 200 27 N c 15 
Raz 2009 7 39 18 8 39 21 15 78 19 N c 7 
Stevens 2003 7 25 28 10 25 40 17 50 34 y c 16 
Vaisman 2008 18 57 32 5 26 19 23 83 28 N EF 12 
Voigt 2001 5 32 16 5 31 16 10 63 16 y c 16 
Total 77 347 22 52 242 21 129 589 22 
Note. Adapted from "Polyunsaturated fatty acids (PUFA) for attention deficit 
hyperactivity disorder ( ADHD) in children and adolescents," by Gillies et al. , 
2012, The Cochrane Library, 201 2 (7), p. 59. Copyright 2012 by the 
Cochrane Collaboration. n = Number of participants lost to follow-up. 
N = Number of participants . % = Percentage of participants lost to follow-up. 
Med. = Concurrent pharmacological treatment of ADHD permitted? Y =Yes. 
N = No. Suppl. = Supplement Preparation. EF = Enriched Foods. 
C = Capsule. LOS = Length of Study in Weeks. 
There are several noteworthy differences between the present study and this 
group of studies. None of these studies used a syrup preparation of PUFA supplements. 
Five of these studies used capsules [18, 39, 22, 24, 17] , while 2 used foods enriched 
with PUFAs [23, 16]. Four studies did not permit the concurrent use of conventional 
pharmacotherapy for ADHD, including stimulants [18, 39, 23, 17]. These studies varied 
in length, from 7- 8 weeks [39, 16], to 12 [23], 15-16 [18, 22, 24], and 24 weeks [17]. Three 
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of these studies made note of inter-visit telephone follow-up by a research assistant, 
with a weekly [23], or biweekly frequency [17, 18]. The remaining studies did not make 
note of their follow-up procedures beyond the frequency of in-person visits. 
5.3.2 Frequency of Follow-up 
This st udy was designed to reflect regular clinical practice, which in the case of youth 
with ADHD and stable treatment would not be intensive. The frequency of follow-up 
varies from clinician to clinician, but visits every 2 months in this circumstance would 
be typical [4] . Follow-up of greater frequency may have improved study retention but 
may not have reflected typical clinical conditions, limiting the generalizability of the 
study results. However , the addition of a new treatment, even a dietary supplement, 
would warrant au increased frequency of follow-up, thus reflecting routi11e clinical care: 
Both study groups would have been t reated in the same manner , negating the effect 
of this increased visit frequency as a confounding variable. 
The studies reviewed in the Cochrane review [7] conducted in-person clinician 
follow-up at similar frequencies to the present study, ranging from approximately 6 
to 8 weeks. Given the similar frequency of in-person follow-up but markedly different 
rates of study withdrawal, it is unlikely that the frequency of follow-up significantly 
cont ributed to the study's high proportion of non-completion. 
5.3.3 Inter-visit Te lephone Contact 
There was no scheduled inter-visit telephone contact in the study protocol. Study par-
ticipants and their guardians were able to call with questions and concerns. Regularly 
scheduled telephone contact with a research nurse may have addressed participant 
and guardian concerns and questions prior to study drop-out. It may be that the 
addition of this dietary supplement may have resulted in greater concern than the 
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use of prescribed medications. Study participants were required to be taking stable 
doses of their medications, implying a level of familiarity and possibly of comfort with 
their medication(s). This dietary supplement may have been perceived as unknown 
and untested, particularly with the added question of whether they were receiving the 
active supplement or the placebo. 
The intent of this design was to reflect clinical practice and to enhance gener-
alizability, as in the case of follow-up visit frequency. Scheduled inter-visit telephone 
contact, particularly with a nurse or other health professional affiliated with t he treat-
ing physician is used in some settings but not in others [4]. Thus, scheduled inter-visit 
telephone contact by a research nurse would likely have improved study retention and 
completion; such telephone contact should be included as part of the protocol of any 
future similar study. 
5.3.4 Length of Study 
The study was designed for 6 months in length to assess for bot h short-term and 
longer-term outcomes of adding omega-3 fatty acid supplements to stably treated 
patients with ADHD, reflecting the goals of generalizability and clinical applicability. 
A shorter clinical trial, particularly with more frequent in-clinic follow-up and inter-
visit telephone contact may have improved study retention and completion, but may 
have compromised the study's generalizability and clinical applicability. 
5.3.5 Participant Characteristics 
The study population was derived from a sub-speciality clinic in a tertiary hospital 
(section 3.5). As a result of this aspect of study design, there may be some participant 
characteristics that made them poor candidates to participate in this clinical trial. An 
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example of this is a high rate (approximately one-third) of missed appointments in 
this clinic population (anecdotal). 
While a review of randomized clinical trials of PUFAs for ADHD in children 
and adolescents [7] was conducted , participant characteristics were not consistently 
reported among these studies, preventing any meaningful or coherent comparison with 
participant characteristics in this study. 
5.3.5.1 Severity of ADHD 
Study participants had considerable residual ADHD-related symptomatology at base-
line in spite of stable and often maximal treatment (subsection 4.2.1, subsection 5.2.1 , 
Figure 4.4, Figure 4.5, Table 4.4, Table 4.5 and Figure 4.6). This may reflect the nature 
of ADHD in general or may reflect the nature of this clinic population [2, 1]. Inherent 
to the diagnosis, these study participants would struggle with impulsivity, making 
compliance with a study protocol challenging. Such a group might be quick to give up 
on a new treatment if they were to encounter challenges, such as adjusting to a new 
treatment routine, particularly if they disliked some aspect of it, such as the taste or 
method of delivery (syrup). 
5.3.5.2 Oppositionality 
As described in subsection 4.2.1, many study participants had problems with opposi-
tionality, as indicated by elevated baseline parent and teacher Conners- 3 Oppositional 
Defiant Disorder sub-test scores (Figure 4.5 , Table 4.4, Table 4.5 and Figure 4.6). 
This is noteworthy for several reasons. Initially, a comorbid diagnosis of Disruptive Be-
haviour Disorder meant exclusion from study participation. As discussed in section 3.3, 
this restraint was later lifted to promote study recruitment. Five of the 14 study par-
ticipants had a comorbid diagnosis involving disruptive disorders, including Disruptive 
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Behaviour Disorder: Not Otherwise Specified (2), Opposit ional Defiant Disorder (1), 
Conduct Disorder (1) , and Adjustment Disorder with Disturbance of Conduct (1). 
This suggests that many of the study participants had clinically significant problems 
with disruptive behaviours in spite of stable and often maximal medical management , 
several of whom were not diagnosed with a comorbid disruptive behaviour disorder 
even though both teacher and parent reports indicated elevated concerns. It is possi-
ble these behavioural concerns were not apparent in t he clinical setting or that the 
clinicians did not consider these symptoms to be of sufficient severity to warrant an 
additional diagnosis. 
Similar to the considerable residual ADHD symptomatology, oppositionality 
may have influenced study completion. Study participants with greater degrees of 
oppositionality may have been more likely to refuse their study supplement, particularly 
if they were having any other issues, such as disliking the supplement or having adverse 
effects. Further, parents and guardians, already struggling with oppositional behaviour 
in the home may have been more likely to abandon the supplement in the face of 
increased oppositionality, particularly if they were facing other issues, as noted above. 
5 .3.5.3 Comorbidities 
Study participants were diagnosed with a median of 1.5 comorbid diagnoses (subsec-
tion 4.1.4, subsection 5.1.4, Table 4.3) . ·while the number and types of comorbidities 
were comparable within groups and comparable to this clinical population, this is still 
a large number. It is possible that the burden of living and dealing with these other 
diagnoses in addition to t heir ADHD and participating in this trial may have predis-
posed these participants to withdraw from the study early. These participants could 
have a reduced capacity to tolerate addit ional demands on their t ime and attention , 
such as taking a supplement in addition to their existing medications. 
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Study part icipants were prescribed a median of 1.5 medications per day, cor-
responding with the median of 1.5 comorbid diagnoses. As noted in subsection 4.1.5 , 
there was a significant difference between this median of 1.5 medicat ions per day and 1 
medication per day, which would be their ADHD-specific treatment . This prescription 
of additional medications for comorbid illnesses suggests that these participants and 
their caregivers were already taking and administering multiple medications per day, 
likely several times per day. The administration times of each medication were not 
consist ently recorded with sufficient precision to permit comment on the number of 
times per day participants were t aking medications (daily medications were often 
recorded as "OD" or "daily", instead of specifying the time of day of administration). 
It is possible that the addition of the study supplement to already complex medication 
administration schedules may have contributed to premature study withdrawal. 
A Cox Proportional Hazards Regression model of the number of medications, 
comorbidities , the severity of participant ADHD, and treatment assignment yielded 
no significant relationships with time in study (i.e. survival t ime) (subsection 4.3.2). 
The absence of a statistically significant correlation could reflect the absence of a 
relationship, or could be t he effect of small sample size. 
5.3.6 Caregiver Characteristics 
No demographic information was collected concerning the caregivers of study partic-
ipants. There may have been caregiver characteristics which predisposed this study 
population to early study withdrawal. 
There is a high prevalence of Adult ADHD among biological parents of children 
with ADHD because of the inheritable nature of the illness [1]. Parents struggling 
with ADHD would have the same issues wit h inatt ention and impulsivity t hat could 
increase the likelihood of poor study compliance and possibly early study termination. 
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Inattention could result in problems such as missed or inconsistently administered 
medications and supplements, and an aversion to the routine of administering treat-
ments, particularly a liquid supplement requiring careful measurement, cleanup and 
refrigerated storage. All of these individually minor impediments could cumulatively 
result in suboptimal protocol complianc . Study participants could also be sensitive 
to this possible caregiver resistance, which in turn could shape their attitudes towards 
study participat ion. 
No direct measures of caregiver burden were made. Caregiver stress may have 
affected patient outcomes and could have impacted study retention and compliance. 
As discussed in subsubsection 5.2.1.2, parent ratings on the Conners 3 reports were 
significantly higher than teacher ratings in most cases (7 of 13 subtests, including 
the Global Index: Total) (Table 4.4, Table 4.5, Figure 4.5, Table 4.6, Figure 4.6, & 
Figure 4. 7). This elevation could represent heightened caregiver stress, with greater 
apparent difficulties and symptomatology in the home, or an increased sensit ivity to 
these problems due to stress. This stre in turn may have affected tudy retention. 
5.3. 7 Implications as a Pilot Study 
As a pilot study, the high rate of of study withdrawal and low rat of study completion 
highlight problems with the feasibility of this design. The study protocol could be 
redesigned to address some or all of the identified concerns and a new pilot study run. 
This is explored further in section 6.5. 
5.3.8 Survival Curves 
Though there was no significant difference in t ime to study withdrawal between the 
two treatment group , there was a trend towards earlier dropout by active group 
participants (section 4.3) . This may reflect a real difference in survival between the e 
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two groups that was unable to be detected due to small sample size, or it may be an 
anomaly, the result of a small change having a large effect on a small sample size. 
5.3.9 Reasons for Withdrawal 
As described in subsection 4.3.1, the high proportion of study participants withdraw-
ing wit h complaints of taste/aftertaste or miscellaneous gastrointestinal complaints 
suggests a problem with the tolerability of both the active and placebo supplements 
(Table 4.9). This is discussed further in subsection 5.3.10. 
The development of a fish allergy is a known adverse effect that occurs in other 
studies involving fish-products. 
It is difficult to interpret the study withdrawals for "unrelated reasons" and a 
"fear of side-effects". These withdrawals account for 25% of the total. These withdrawals 
could be interpreted as actually unrelated, or t hey could suggest other, unidentified 
reasons for withdrawal that were not adequately addressed or queried. 
5 .3 .10 Tolerability/ Adverse Effects 
It is difficult to meaningfully compare the tolerability of the supplements used in 
this trial to those in published trials, as the form of the these supplements have 
differed, wit h most studies using capsules or gummies. The liquid supplement may 
be a poor choice for children and teens because of these problems with tolerability 
(subsection 4.3.3). The Cochrane review [7] did not identify any differences in the rates 
of adverse effects between groups. 
There was no space on the AEI form to solicit or record adverse effects not 
specifically recorded on the form. It is possible t hat participants experienced other 
adverse effects that were not captured and analyzed. 
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5.3.11 Supplement Formulation 
There were no clinical trials assessed by the Cochrane review [7] that employed a syrup 
preparation of an omega- 3 fatty acid supplement (Table 5.1). It is therefore difficult 
to gauge the effect of supplement preparation on study completion in comparison to 
other studies and other supplement formulations. 
Two participants in each t reatment group (33%) cited taste/ aftertaste as t heir 
reason for study withdrawal (Table 4.9, subsection 4.3.1) . An additional 1 participant 
in the active group and 2 in the placebo group (25%) cited gastrointestinal complaints 
as their reason for withdrawal. A total of 7 participants (58%) cited taste, aftertaste or 
gastrointestinal complaints as their reasons for withdrawal. This is likely noteworthy 
and suggests the tolerability of the supplement and placebo was a major contributing 
factor to high rates of study withdrawal. 
All study part icipants who returned for the first follow-up clinic visit completed 
an AEI (Appendix B) and endorsed adverse effects at some point during the trial. Many 
of these adverse effects were gastrointest inal in nat ure and may be more problematic in 
a syrup preparation of an omega-3 fatty acid supplement. However, adverse effects were 
reported more often by participants in the placebo group , though not to a statistically 
significant extent. This may suggest the supplement formulat ion, independent of omega-
3 fatty acid content, may have been difficult to tolerate, particularly in comparison to 
other omega- 3 fatty acid supplement preparations, and may have therefore contributed 
to study withdrawal, independent of omega- 3 fatty acid content. 
5.4 Outcomes 
As noted in section 4.4, several of the planned outcome measure analyses were not 
performed because only one study participant per group completed the t rial and two 
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of these measures , the Conners 3: Parent and Teacher Reports were only performed 
at the beginning and end of the trial, precluding even an LOCF analysis of this data. 
The remaining measures were analyzed using an LOCF approach. 
5.4.1 ADHD Severity Measures 
5.4.1.1 Conners Continuous Performance Test II 
·while there was no significant difference in the change in CCPT -CI scores between 
treatment groups , the trend in the data was towards an improvement (decrease) in 
CCPT-CI scores in the active group and a worsening (increase) in CCPT-CI scores in 
the placebo group ( subsubsection 4.4.1.1). It is possible that these trends are artifacts 
of these small data sets with high variability, as evidenced by the 95% confidence 
intervals which extend past the range of possible values in some cases (Table 4.12 and 
Figure 4.8) . 
5.4.1.2 Conners 3: Teacher & Parent Reports 
As noted in section 4.4 and section 5.4, analysis of Conners 3: Teacher and Parent 
Report data was not possible because these measures were conducted at the beginning 
and end of the study protocol, meaning only those participants completing the study 
would be included in t hese measures, and only one participant per group completed 
the protocol. 
5.4.2 Clinical Global Impression Scale 
Using an LOCF approach, there was no identifiable difference between the mean 
CGI scale scores of the active and placebo groups (subsection 4.4.2, Table 4.13 and 
Figure 4.9). There are several possible interpretations of this finding beyond the 
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literal interpretation that there was no difference in these outcomes. As the majority 
of subject data included in this analysis was carried forward due to study dropout , 
any change which might have occurred later in the study period would have been 
missed. The missing data due to loss to followup might be substantially different from 
that analyzed. T his difference could favour either treatment group. A change in this 
outcome might have been observable even at an early stage of study outcome but may 
have been undetected due to the small sample size. 
5.4.3 Signs of Omega- 3 Fatty Acid D eficiency 
With one measurement from the active group and two from the placebo group, it is 
impossible to draw any meaningful conclusions from the analysis of the TSQ data 
(subsect ion 4.4.3 and Figure 4.10). 
Chapter 6 
Conclusions 
6.1 -Outcomes 
6.1.1 Primary Outcomes 
Due to t he high rate of dropout, it was not feasible to draw conclusions regarding 
the effects of omega- 3 fatty acid supplementation on youth wit h ADHD, as measured 
by the C3T-T. In a meta-analysis , similar studies have not reported a statistically 
significant difference between placebo and active supplementation [7]. 
6.1.2 Secondary Outcomes 
Similarly, due to t he high rat e of dropout , it was not feasible to draw conclusions 
regarding t he effects of omega- 3 fatty acid supplementation on youth with ADHD, as 
measured by the C3P-T , the CCPT-CI, or the CGI clinical improvement scale. 
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6.1.3 Survival Analysis 
A post hoc survival analysis, discussed in section 4.3 and subsection 5.3.8 did not 
identify any difference between study groups in the time to study withdrawal. It 
appears study withdrawal was not related to the omega-3 content of the supplement; 
this suggests that neither the presence nor the absence of omega-3 appeared to confer 
any benefit in terms of remaining in the study. It is possible that a difference was not 
detected due to small sample sizes. This finding is compatible with similar studies 
finding no difference in study withdrawal based on treatment a signment [7]. 
6.2 Patient Characteristics 
6.2.1 ADHD Symptomatology 
Based on the initial assessments, this clinical population had considerable residual 
ADHD symptomatology, as measured by the Conners-3 Teacher and Parent reports. 
This is noteworthy as all patients in this study were on stable and likely maximal 
pharmacotherapy for their ADHD. Also noteworthy is the discrepancy between these 
subjective reports and the objective results of t he CCPT-II, which did not detect 
the same levels of clinically significant residual symptomatology. This suggests these 
assessment tools measure different aspects of this complex condition and that current 
pharmacotherapies preferentially target and improve these objectively measurable 
symptoms, while leaving these other clinical challenges largely unmet. The severity of 
ADHD in this study population was generally greater than that of subjects in similar 
studies [7]. 
Though bot h teachers and parents reported clinically significant levels of ADHD 
symptomatology on the Conners- 3 assessments, parent ratings were significantly 
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greater than t eachers'. This suggests several possible conclusions, including different 
perceptions of the same signs and symptoms by these two groups; different observable 
behaviour by the youth in these different contexts; different challenges and therefore 
different signs and symptoms evident in different environments; and diminished tol-
erance among caregivers for the same difficulties, possibly due to caregiver fatigue. 
This difference was not observed in similar studies [7]. Given the high level of ADHD 
severity in the study population and the difference between this study population and 
those iu similar studies, this difference in rating between teachers and caregivers may 
be a function of this heightened severity and thus may not have been seen in other 
studies working with less impaired populations. 
6.2.2 Comorbidities 
The study participants had high rates of comorbidity as indicated by recorded comorbid 
diagnoses as well as polypharmacy, suggesting a high burden of illness for these patients 
as well as a high caregiver burden. 
6.2.3 Signs of Omega- 3 Fatty Acid Deficiency 
On average, the clinic and study population had mild to moderate signs and symptoms 
of omega-3 fatty acid deficiency, as measured by the TSQ. This finding was less than 
expectecl, possibly due to a higher than average dietary intake of omega-3 fatty acids 
from fish or dietary supplementation. Anecdotally, Newfoundlanders have historically 
had diets which were high in omega- 3 fatty acids from seafood. Also anecdotally, many 
foods are now fortified with omega- 3 fatty acids. Concerned parents of youth with 
ADHD might be likely to give these foods to their children , much as they might enrol 
t hem in this study. Baseline omega- 3 dietary intake and supplementation was not 
screened or adjusted for. A dietary log could be added to a revised protocol. 
CHAPTER 6. CONCLUSIONS 86 
6.3 Study Protocol 
The high rate of participant dropout suggests several possible limitations in this study 
and opportunities for refining the protocol. As a clinical trial, this outcome resulted 
in an inability to evaluate the study's hypothesis. As a pilot study, this is part of an 
iterative cycle of protocol refinement. Important limitations are outlined in section 6.5, 
which discusses their implications as a pilot study and potential changes to the protocol. 
6.4 Limitations 
6.4.1 Dropout 
The high rate of participant dropout was a limitation of this study. Numerous possible 
explanations were explored in the discussion section. Due to the high dropout rate it 
is not feasible to draw conclusions regarding the effects of omega- 3 fatty acid supple-
mentation in the treatment of ADHD. It also suggests there may be problems with the 
study design , protocol, recruitment and retention strategies, choice of study population 
and choice of supplement. Study protocol refinements to address these problems with 
participant retention in addition to other deficits are outlined in section 6.5. 
6.4.2 Inability to Conduct Planned Analyses of Data 
This high rate of participant dropout prevented several planned analyses, including 
the analyses of the primary outcome measures. 
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6.4.3 Change in Protocol 
The change in study protocol, expanding the inclusion criteria highlights a limitation 
of the original protocol. The original inclusion/exclusion criteria was evidently too 
restrictive and less clinically relevant in an attempt to recruit a relatively homogeneous 
study population with few confounding factors. 
6.4.4 Study Site 
The choice of a single study site, part icularly a subspecialty clinic, while convenient , 
was a limitation. It resulted in a relatively small base of patients from whom to recruit. 
This limitation was compounded by the initially restrictive inclusion/exclusion criteria. 
This may have excluded many potential participants with high levels of symptom 
severity and high rates of comorbidity that were likely present in this subspecialty 
clinic population. 
6.4.5 Failure to Recruit _Full Complement for Study 
The failure to recruit the planned number of study participants was a limitation. 
This was unforeseen and highlights the importance of this research as a pilot study. 
Inadequate sample size compounded the unexpectedly high dropout rates to prevent 
detection of the differences in outcomes that it was powered to detect . The choice of 
study site and to a lesser extent, the inclusion/exclusion criteria were likely contributing 
factors. Recruitment strategies, including advertisement of the study to patients and 
physicians seemed adequate, but may also warrant optimization. Recruitment strategies 
are discussed in subsection 6.5.2. 
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6 .4.6 Last Observat ion Carried Forward 
As noted in subsection 3.12.2, section 4.4 and section 5.4, an a priori decision was 
made to use an LOCF approach for missing data. This means of analysis can introduce 
bias [46] . This bias includes a tendency to favour interventions that may be efficacious 
but difficult to tolerate. This method treats dropouts from each treatment group 
identically. However, it is possible that study participants may have dropped out for 
different reasons and ultimately fared different ly in terms of outcomes. In the case of 
this study, the reasons for study withdrawal were captured in an unstructured manner. 
There did not appear to be a marked difference between the groups in terms of reasons 
for withdrawal. However , this does not imply the groups would have fared similarly 
in t erms of outcomes. 
6.5 Role as a Pilot Study 
\iVhile this study was unable to meet its primary goal of assessing the efficacy of 
sunplementing children and arl.olescents with ADHD with omega- 3 fatty acids, it did 
serve its other role as a pilot study very well, assessing feasibility and practicality 
while suggesting refinements and modifications to future studies. 
6.5.1 Study Site 
Future studies will require a larger referral base, preferably from primary care, in-
cluding family doctors and nurse practitioners, as well as specialist care, including 
paediatricians and community psychiatrists. These patient populations will ensure a 
high degree of clinical applicability. The use of multiple study sites will help minimize 
the influence of site-specific effects on study outcomes. The use of multiple sites does 
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introduce additional logistical challenges, which could have unforeseen consequences 
that cannot be planned for based on this study. A study coordinator or full-t ime 
research nurse would need to be employed to monitor this sort of study. 
The benefits associated with the inclusion of sub-speciality services, such as child 
and adolescent psychiatry and developmental paediatrics is debatable. The referral 
base should not be restricted to these last groups. These last groups could serve as a 
valuable source of study participants with higher levels of symptomatology and more 
challenging comorbidities, which would enhance the generalizability of study results. 
For the same reasons, t hese patients may be more difficult to maintain in this sort of 
study, resulting in high dropout rates . 
6.5.2 Recruitment 
In addition to expanding the referral base by adding additional study sites, as discussed 
in subsection 6.5.1 , patient recruitment could also be enhanced by increasing awareness 
among both recruiting physicians and eligible patients. 
Additional study sites could be arranged by contacting physicians already 
familiar to the study team. T hese physicians could be asked to suggest other physicians 
that might be willing to establish a study site. Letters and/ or emails of introduction 
could be used to initiate this process. In addition, the Newfoundland and Labrador 
Medical Association (NLMA) or Medical Care Plan (MCP) mailing lists could be used 
to distribute such a letter of introduction, outlining the study and inviting interested 
parties to contact the principal investigator. 
Eligible patients could be made aware of the study by distributing a similar let-
ter of introduction through mailing lists that would include the parents and guardians 
of these youths, including The Newfoundland and Labrador Tourette's Foundation, 
and The Newfoundland and Labrador Learning Disabilities Association. If necessary, 
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a wider audience could be reached with study advertisements in the media, including 
newspapers and radio. 
6.5.3 Inclusion/Exclusion Criteria 
This study 's modified inclusion/exclusion criteria could serve as a reasonable basis for 
future studies. It includes compromises to help ensure a sufficiently homogeneous study 
population to permit treatment effects to be detected without being overwhelmed by 
confounders. It represents a population that is clinically relevant to both primary and 
specialist care. A proposed study's sample size will need to be increased to account 
for this increase in sample heterogeneity. 
6.5.4 Sample Size 
Were the study protocol to remain the same, sample size estimates would have to 
account for a high dropout rate. However, with the proposed changes to this study 
protocol, estimates of study dropout rates could be based on the trials reviewed in 
the Cochrane review, with a mean dropout rate of 22% (Table 5.1) [7] . 
6.5.5 Study Length 
The study length of 6 months could remain unchanged in a future trial. As discussed in 
subsection 1.1.4 and subsection 3.1.1, the length of time to the onset of any therapeutic 
action and the duration of this action are unknown at present [7]. Therefore, the study 
length should remain as long as is practical. Otherwise, failure to identify a t herapeutic 
effect could be due to a brief study duration. Also, identifying a therapeutic effect 
during a brief trial would not necessarily imply a long-lasting therapeutic effect. 
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One trial in the Cochrane review [7] was 6 months in length [17]. As discussed 
in subsection 5.3.1 and Table 5.1, t he dropout rate of this trial was comparable with 
the shorter studies in the review (15% vs. 22%). Once the other protocol changes 
discussed in this section have been incorporated, it is likely the dropout rate for a 
future trial would be comparable to published rates and not negatively affected by a 
study length of 6 months. 
6 .5.6 Choice of Supplement 
In spite of informal assessment of palatability of the supplement and placebo, this ap-
pears to have been a barrier to study completion. A short list of potential supplements 
could be gathered from the clinical trials in the Cochrane review [7]. Any recently 
introduced supplements t hat might be appropriate could also be considered. More 
extensive tests of palatability could then be conducted to ensure potential supplements 
are acceptable to local children and adolescents. The final choice of supplement could 
then be based on a combination of palatability and other factors, such as omega-3 
composition and supplement preparation (e.g. capsule vs. liquid) . 
6 .5. 7 Frequency of Follow-Up 
The present study's frequency of clinic follow-up (every 8 weeks) was similar to other 
studies [7] and could remain unchanged in a future trial. The lack of regular inter-visit 
telephone follow-up by a research nurse likely contributed to the high rate of dropout 
and should be corrected in future protocols. Based on other studies, telephone contact 
every 2 to 4 weeks seems to be the optimal frequency [7]. 
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6.5.8 Outcome Measures 
The choice of primary and secondary outcome measures in this protocol are compat ible 
with similar studies [7]. The combination of objective measures, including, the CCPT-II 
and CCI, and subjective measures, the Conners-3 reports provided a multidimensional 
perspective on t reatment effects. These outcome measures were administered without 
notable difficulty. They could be reused in a fu ture protocol. 
The TSQ was consistently administered, although the results were not entirely 
as expected or in keeping with other studies [7] . This is likely not a limitation of this 
validated and widely used tool. This discrepancy is more likely attributable to the small 
sample size and possible cultural and dietary factors discussed in subsection 6.2.3. 
The AEI was effective in assessing tolerability. A useful addition to this tool 
would be the addition of an "Other" option, with space to elaborate on the adverse 
effect and make comments. 
A study withdrawal form would be useful in a revised protocol. A process 
whereby a research assistant or nurse routinely calls participants that have withdrawn 
from the study could be added to the study protocol and consent process. The reasons 
for withdrawal collected during this study could be used as the basis for such a 
form, including: Taste/ Aftertaste, Gastrointestinal Complaints, Developed Fish Allergy, 
Factors Unrelated to Study, and Lack of Efficacy. Like the AEI, an additional option 
of "Other" could be added, with additional space for notes and comments. 
6.6 Summary 
This study had several limitations, including problems with recruitment, initially re-
strictive inclusion criteria, early study withdrawal, and a supplement and placebo 
with low tolerability. Several of the planned analyses could not be performed due to 
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small sample size. The analyses that were conducted relied heavily on LOCF data. 
Conclusions specific to t he null hypothesis cannot be drawn from the results of the 
planned analyses that were able to be conducted. There was no statistically significant 
differences between the groups. No conclusions can be made regarding the efficacy of 
this omega- 3 supplement in the treatment of ADHD based on this st udy. 
As a pilot study, t hese limitations highlight some of the necessary changes to 
the study protocol. Some of the key changes include finding and using a more tolerable 
supplement and placebo, using multiple, non-sub-specialty sites for patient recruitment, 
broader inclusion criteria, and between visit telephone contact. 
Appendix A 
Clinical Global Impression Scale 
Clinica l Globa.l Impression (CGI) 
I . Severity of illness 
Considering your total clinical experience w ith this particular population, how mentally ill is the patient at this time! 
0 = Not assessed 4 = Moderately ill 
I = Normal, not at all ill 5 = Markedly ill 
2 = Borderline mentally ill 
3 =Mildly ill 
6 = Severely ill 
7 = Among the most extremely ill patients 
2 . G lobal impr ovement: Rate total improvement whether or not, in your judgement, it is due entirely to drug t reatment. 
Compared ro his condition at admission to the project, how much has he changed? 
0 = Not assessed 4 = No change 
I = Very much improved 5 = Minimally worse 
2 = Much im proved 6 = Much worse 
3 = Minimally improved 7 = Very much worse 
3. Efficacy index: Rate this item on the basis of drug effect only. 
Select the terms which best describe the degrees of therapeutic effect and side effects and record the numbe r in the box whe re the two 
items intersect. 
EXAMPLE: Therapeutic effect is rated as 'Moderate' and side effects are judged 'Do not significantly interfere with patient 's functioning'. 
Therapeutic effect Side e ffects 
None Do not significantly 
Marked Vast improvement. Complete or nearly complete 0 I 
remission of all symptoms 
Moderate Decided improvement. Partial remission of OS 
symptoms 
Minimal Slight improvement which doesn't alter status 
of care of patient 
Unchanged or worse 
Not assessed = 00 
09 
13 
interfere with 
patient's functioning 
02 
06 
10 
14 
Signi(tcantfy interferes Outweighs 
with patient's therapeutic 
funaioning effect 
03 04 
07 08 
II 12 
15 16 
Reproduced from Guy W, editor . ECDEU Assessment Manual for Psychopharmacology. 1976. Rockville , MD, U.S. Department of Health, 
Education. and W elfare 
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Appendix B 
Adverse Effect Inquiry Form 
Patient Number: 
Side Effect: Yes No 
Belching 0 0 
Nausea 0 0 
Diarrhea 0 0 
Bloating 0 0 
Intestinal Gas 0 0 
Fishy Body Odour 0 0 
Fish Breath 0 0 
Fishy aftertaste 0 0 
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Appendix D 
Omega-3 Fatty Acid Supplement 
Table D.1: Genius Liquid Kids And Teens - Omega-3: Formulation Per 5 mL Serving 
Ingredient mg 
Wild tuna fish oil 1000 
\Vild fish oil blend (mackerel, anchovy, sardine) 1000 
Certified Organic Flax seed oil, ( Linum usitatissimum) Cold Pressed 320 
Borage oil (Baraga officinalis) (20% GLA) 150 
Soy lecithin (Glycine max, bean) rich in Phosphatidyl choline ( 4.5 mg) 15 
Vitamin E (d-alpha-tocopherol) 9 
Antioxidant blend 
Rosemary extract 
atural Orange Flavour 
Nate. Adapted from Genius Liquid Kids And Teens - Omega-3, by 
Nutripur, 2013. Retrieved from http: / / www.nutripur.com/ 
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Table D.2: Genius Liquid Kids And Teens - Omega-3: Polyunsaturated Fatty Acid 
Content Per 5 mL Serving 
Polyunsaturated Fatty Acid mg 
Omega-3 
Docosahexaenoic acid (DHA) 365 
Eicosapentaenoic acid (EPA) 225 
Alpha-Linolenic acid (ALA)) 160 
Omega-6 
Gamma-Linolenic acid (GLA) 30 
Linoleic Acid (LA) 90 
Arachidonic acid (AA) 15 
Nate. Adapted from Genius Liquid 
Kids And Teens- Omega-3, 
by Nutripur, 2013. Retrieved from 
http:/ / www.nutripur.com/ 
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